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Summary 
Clear-cell subtype is the most frequent and aggressive form of renal cell carcinoma and is highly 
metastatic, leaving the patients with a very poor prognosis. Metastatic ccRCC is mainly treated 
with small molecules therapies with anti-angiogenic properties. Despite recent advances in that 
matter, ccRCC seems to be intrinsically resistant or acquire resistance to these treatments. Von-
Hippel Lindau tumor-suppressor gene (VHL) inactivation occurring in almost 90% of the ccRCC 
cases has been proven to be a critical and early event in tumor initiation. This high rate of 
alteration led researchers to focus on this gene to unravel its implication in ccRCC development 
and to evaluate its potential as a prognostic or predictive biomarker. Most of the current research 
tend to concentrate on VHL protein’s (pVHL) best studied function: the downregulation of the 
hypoxia inducible factor (HIF). However, as a multiadaptor protein, pVHL is also involved in 
many other oncogenic processes. The overall goal of my PhD thesis was to investigate i. VHL 
mutations, and especially missense mutations; ii. the pathways that could be affected and iii. the 
way those mutations can influence cell behavior with or without treatment. We found that some 
of pVHL binding domains were preferentially altered by missense mutations: HIF1AN, 
BCL2L11, HIF1/2α, RPB1, PRKCZ, aPKC-λ/ι, EEF1A1, CCT-ζ-2, and Cullin2 binding regions 
were indeed more frequently affected by missense mutations than what is expected by chance. 
Those interactors and the pathways in which they are involved may represent interesting new 
therapeutic targets. One potential binding protein of pVHL is the tumor suppressor p53 whose 
gene is rarely mutated in ccRCC but downregulated in most of the tumors. We studied the 
different effects of particular VHL missense mutations on p53 signaling pathway and found that 
all mutations influenced more or less p53 transactivation, which in turn differently attenuated 
apoptosis of the mutated cells. The use of a p53-mediated pro-apoptotic drug, Camptothecin, may 
therefore be a promising way of treating ccRCC. Since VHL inactivation alone cannot explain 
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ccRCC development and treatment resistance, we attempted to unravel variants clusters among 
400 cancer-related genes that could be related to the response to current treatments of ccRCC 
patients using next-generation sequencing. Of the genes known to be important in ccRCC, VHL, 
PBRM1, SETD2, MTOR and PDGFRA were the most frequently altered ones in our cohort. 
Responder patients were presenting in general more variants than non-responders in the genes 
PBRM1, BAP1, CARD11 and HIF1α.  
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Zusammenfassung 
Der klarzellige Subtyp ist die häufigste und zugleich aggressivste Form des Nierenzellkarzinoms 
(NZK), hat hohes Meatastasierungspotenzial und geht einher mit einer schlechten Prognose. 
Metastasierte klarzellige NZK werden mit kleinen Molekülen behandelt, welche die 
Blutgefässneubildung hemmen. Trotz erzielter Fortschritte mit dieser Therapie, scheint das 
klarzellige NZK oft gegen diese Behandlung resistent zu sein beziehungsweise resistent zu 
werden. Das Von-Hippel Lindau Tumorsuppressorgen (VHL) ist in fast 90% der klarzelligen 
NZK inaktiviert und stellt ein kritisches und frühes Ereignis bei der Tumorentstehung dar. Die 
hohe Mutationsrate führte Forscher dazu dieses Gen näher zu betrachten, um seine Beteiligung an 
der Entwicklung des klarzelligen NZK sowie sein Potenzial als prognostischer oder prädiktiver 
Biomarker zu untersuchen. Die gegenwärtige Forschung fokussiert sich hauptsächlich auf die am 
besten untersuchte Funktion des VHL Proteins: die negative Regulation des Hypoxie-
induzierbaren Faktors. pVHL ist jedoch als Multiadaptor Protein noch in vielen anderen 
Tumorprozessen involviert. Das Hauptziel meiner Doktorarbeit war die Untersuchung von VHL 
Mutationen, insbesondere Missense Mutationen, die durch sie betroffenen molekularen 
Signalwege sowie die Art und Weise, wie diese Mutationen Zelleigenschaften mit oder ohne 
Behandlung beeinflussen. Wir fanden heraus, dass einige der pVHL Bindungsdomänen 
bevorzugt von Missense Mutationen betroffen sind: Die Bindungsregionen von HIF1AN, 
BCL2L11, HIF1/2α, RPB1, PRKCZ, aPKC-λ/ι, EEF1A1, CCT-ζ-2 und Cullin2 waren in der Tat 
häufiger mutiert als zufällig erwartet. Diese pVHL Bindungspartner und die molekularen 
Signalwege, an welchen sie beteiligt sind, könnten somit interessante neue Therapieziele 
repräsentieren. Ein potenzielles Bindungsprotein von pVHL ist auch der Tumorsuppressor p53, 
dessen Gen in klarzelligen NZK kaum mutiert ist, aber in den meisten Fällen nicht exprimiert ist. 
Wir analysierten die unterschiedlichen Effekte bestimmter VHL Missense Mutationen auf den 
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p53 Signalweg und fanden, dass alle Mutationen mehr oder weniger die p53 Transaktivierung 
beeinflussten und somit unterschiedlich die Apoptose von Zellen abschwächten. Die Anwendung 
des p53 aktivierenden, Apoptose fördernden Medikaments Camptothecin könnte daher ein 
vielversprechender Weg sein, klarzellige NZK zu behandeln. Da die Inaktivierung von VHL 
alleine nicht ausreicht, um die NZK-Entstehung und die Behandlungsresistenz zu erklären, wurde 
mittels Next-Generation-Sequencing versucht, Mutationsmuster unter 400 krebsrelevanten Genen 
zu finden, die mit dem Ansprechen von klarzelligen NZK Patienten auf gegenwärtig 
durchgeführte Behandlungen korrelieren. Von den bekannten NZK-relevanten Genen waren 
VHL, PBRM1, SETD2, MTOR und PDGFRA die am häufigsten mutierten in unserer Kohorte. 
Patienten, die auf die Therapie ansprachen, wiesen generell mehr Varianten in den Genen 
PBRM1, BAP1, CARD11 and HIF1α auf als solche, die nicht ansprachen.  
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Résumé 
Le carcinome du rein à cellules claires est la forme la plus fréquente et la plus agressive de cancer 
du rein et est fortement métastatique. Il est ainsi associé à un très mauvais pronostic de survie 
pour les malades. Lorsqu’il est métastatique, ce cancer est principalement traité avec des 
médicaments à visée anti-angiogénique. Malgré les récents progrès dans ce domaine, le 
carcinome du rein à cellules claires semble être intrinsèquement résistant ou acquérir une 
résistance à ces traitements. L’inactivation du gène suppresseur de tumeur Von Hippel-Lindau 
(VHL) survenant dans près de 90% des cas a été démontrée comme étant une étape majeure dans 
l'initiation de la tumeur. Cette fréquence élevée d’inactivation du gène VHL a conduit les 
chercheurs à se concentrer sur ce gène afin d’évaluer son implication dans le développement du 
carcinome du rein à cellules claires ainsi que son potentiel en tant que biomarqueur pronostique 
ou prédictif. La plupart des recherches actuelles sont axées  sur la fonction la plus étudiée de la 
protéine VHL (pVHL): la baisse d’expression des facteurs induits par l'hypoxie (HIF). 
Cependant, étant une protéine à multiples fonctions, pVHL est également impliquée dans de 
nombreux autres processus oncogéniques. L'objectif général de ma thèse a été d'étudier i. les 
mutations de VHL et en particulier les mutations faux-sens, ii. les voies de signalisation qui 
pourraient être altérées et iii. le rôle de ces mutations sur le comportement des cellules avec ou 
sans traitement. Nous avons mis en évidence que certains des domaines de liaison de pVHL sont 
préférentiellement touchés par les mutations faux-sens: les domaines de liaison de HIF1AN, 
BCL2L11, HIF1 / 2a, RPB1, PRKCZ, aPKC-λ / ι, EEF1A1, CCT-ζ-2, et Cullin2. Ces derniers 
ont montré en effet une fréquence de mutations faux-sens significative. Les protéines de liaison et 
les voies de signalisation associées à ces domaines peuvent représenter de nouvelles cibles 
thérapeutiques potentielles. Une protéine de liaison candidate de pVHL est p53, une potéine 
suppresseur de tumeur dont le gène  est rarement muté dans le carcinome du rein à cellules claires 
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mais est sous-exprimé dans la plupart des cas. Nous avons étudié les effets de mutations faux-
sens spécifiques de la voie de signalisation de p53 et avons trouvé que toutes les mutations ont un 
effet plus ou moins important sur la transactivation de p53, ce qui se traduit par une apoptose plus 
ou moins diminuée des cellules mutées. L'utilisation d'un médicament pro-apoptotique dépendant 
de l’activation de p53, la camptothécine, peut donc être un moyen prometteur de traiter le 
carcinome du rein à cellules claires. Puisque la seule inactivation de VHL ne peut pas expliquer le 
développement du carcinome du rein à cellules claires et du fait de la résistance au traitement de 
ce carcinome, nous avons tenté d’identifier des groupes de mutations qui pourraient être liés à la 
réponse aux traitements actuels des patients parmi plus de 400 gènes liés au cancer en utilisant le 
séquençage de nouvelle génération. Parmi les gènes connus pour être importants dans le 
développement du carcinome du rein à cellules claires VHL, PBRM1, SETD2, MTOR et 
PDGFRA étaient les plus fréquemment mutés chez les patients répondeurs au traitement de notre 
cohorte.  Ces derniers présentaient de manière générale plus de mutations dans les gènes PBRM1, 
BAP1, CARD11 et HIF1α que les patients non-répondeurs.  
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I. Introduction 
A. Epidemiology of Renal Cell Carcinoma 
Renal Cell carcinoma (RCC) represents more than 3% of all the cancer types and is the ninth 
most common cancer worldwide [1-3]. In the USA, more than 61’000 new cases and more than 
14000 RCC related deaths have been predicted in 2015. The number of new cases has 
continuously increased over the years, whereas the number of deaths remains stable. The five 
year survival rate has greatly increased in the last 30 years, reaching today 73%. RCC is mainly 
asymptomatic and is usually incidentally diagnosed by computed tomography. The common 
symptoms of RCC are blood in the urine, lump in the abdomen, pain in the side, loss of appetite, 
weight loss, and anemia. The three main risk factors are smoking, obesity, and high blood 
pressure. The median age at time of diagnosis is 64 years (Figure 1) [4]. 
 
Figure 1: Percent of new cases by age group [4]. 
While patients with localized disease have a good prognosis, patients with distant metastasis have 
a five year survival rate of less than 12% (Figure 2). Metastasizing RCC, either present at time of 
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diagnosis (up to 20%) or progressing (20-40%), remain the most challenging feature of patient’s 
disease management after surgical resection of the tumor [5, 6]. 
 
Figure 2 Cases by stage of the disease and related 5-year survival rate [4]. 
B. RCC prognostic parameters 
a. TNM staging 
The TNM staging is a classification system of tumor characterization using 3 categories: “T” 
stands for the description of size and extension of the primary tumor, “N” stands for the regional 
lymph node involvement and “M” for the presence or absence of distant metastatic sites (Table 
1). TNM staging can be divided in two categories: cTNM is based on clinical examination and is 
used for the choice of treatment, and pTNM pathological classification is based on additional 
evidences acquired from surgery and pathological examination providing insights on prognosis 
[7, 8]. Although TNM staging is a good prognostic tool for RCC, it is not suitable for predicting 
the long term evolution of the disease [8].  
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Table 1: TNM staging of RCC.  
Staging Classification Tumor size and extension 
Localized RCC 
T1 Tumor ≤7.0 cm, limited to kidney 
T1α Tumor ≤4 cm, limited to kidney 
T1b Tumor >4 cm and ≤7 cm, limited to kidney 
T2 Tumor >7 cm, limited to kidney 
Locally advanced 
RCC 
T3 Tumor extends into major veins or invades adrenal or perinephric tissues but not? beyond 
  
T3a Perinephric or sinus fat or adrenal extension 
T3b Renal vein or vena cava involvement below diaphragm 
T3c-T4b Vena cava involvement above diaphragm 
Regional lymph 
nodes 
Nx Regional lymph node cannot be assessed 
N0 No regional lymph node metatases 
N1 Metastases in one regional lymph node 
N2 Metastases in more than one regional lymph node 
N3 Metastasis in one lymph node >5 cm  
Distant metastases 
Mx Distant metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases 
 
b. Fuhrman grade 
 Microscopic differentiation grading of RCC is based on the nuclear morphology of the neoplasm 
with hematoxylin and eosin staining. The most widely used system is the 4-tiered Fuhrman 
grading, scored 1 to 4, going along with increasing nuclear size and irregularity as well as 
nucleolar prominence (Table 2). According to Fuhrman et al. [9], nuclear grading is the most 
significant prognostic tool for outcome prediction of stage I renal cell carcinoma. 
Table 2: Fuhrman grading system. Adapted from Sun et al. [10] and Fuhrman et al. [9] 
 Nuclear diameter Nuclear shape Nucleoli 
Grade I Small, 10uM Round, uniform Absent, inconspicuous 
Grade II Larger, 15uM Irregularities in outline Visible at 400x 
Grade III 
Even larger, 20uM Obvious irregular outline 
Prominent at 100x 
Grade IV Bizarre multi-lobed with spindles 
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C. RCC subtypes 
 
Figure 3: Histology of the major RCC subtypes (stained with hematoxylin and eosin). A: clear-
cell renal cell carcinoma; B: Papillary renal-cell carcinoma; C: chromophobe renal cell 
carcinoma.  Adapted from Ficarra et al. [11] 
Three major histological subtypes of RCC exist  (Figure 3): clear cell subtype (ccRCC) (more 
than 75% of the cases), known to be related with inactivation of the Von Hippel-Lindau gene 
(VHL), papillary RCC (10-15% of RCC cases, associated with cMet alterations in its hereditary 
form), and chromophobe RCC (5%, associated with FLCN mutations in Birt-Hogg-Dubé 
syndrome) (Table 3) [12].  
 
Table 3: Characteristics of RCC subtypes and associated hereditary syndromes. Adapted from 
Pavlovich et al. [13]. 
Histological type Cell of origin Genes implicated Associated hereditary syndromes 
Clear-cell renal cell 
carcinoma Proximal renal tubule VHL, FLCN 
Von Hippel-Lindau                         
constitutional chromosome 3 
translocation Birt-Hogg-Dubé 
Papillary renal-cell 
carcinoma Proximal renal tubule 
MET, FH, 
HRPT2 
Hereditary papillary renal carcinoma       
hereditary leiomyomatosis renal-cell 
cancer hyperparathyroïdism-jaw tumor              
familial papillary thyroid cancer 
Chromophobe 
renal-cell 
carcinoma 
Intercalated cell of renal 
collecting duct FLCN Birt-Hogg-Dubé 
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The clear cell subtype, which is the focus of this thesis, is the most common RCC subtype and is 
also the most aggressive form of RCC.  The average size of the primary tumor is 7cm diameter 
and forms globular mass protruding from the renal cortex, presenting a “pushing margins” 
phenotype with a pseudocapsule. ccRCC appears macroscopically as a golden yellow mass due to 
its rich lipid content. 
D. The von-Hippel Lindau gene and protein 
a. Gene, function and pathway 
The VHL gene, located at the 3p25.3 locus in the human genome, is a tumor suppressor gene of 
639 coding nucleotides divided in three exons [14]. The VHL protein (pVHL) can be produced as 
3 different isoforms due to alternative splicing of VHL RNA. Isoform 1 is a 30kDa protein 
located mainly in the cytoplasm. This isoform is composed of 213 amino acids and is the major 
form of pVHL. Isoform 2 differs from isoform 1 by missing amino-acids 114 to 154 that 
normally form exon 2. Isoform 3 comes from the initiation of translation at the Methionine amino 
acid at position 54 and leads to the expression of a 19kDa protein located in the cytoplasm and in 
the nucleus of the cells. pVHL is formed by two tightly coupled domains, α and β. The β-domain 
consists of seven strands arranged in two β-sheets in sandwich with a α-helix, and it has the 
properties of a substrate docking site. The α-domain consists of three α-helices and is known to 
bind Elongin C [15]. pVHL is known to act as substrate recognition in an E3 ubiquitin protein 
ligase complex, called the VBC complex, to target other proteins for proteasomal degradation 
[16, 17]. Additionally to pVHL, this complex is formed by Elongin B and C, Cullin2 and Rbx-1.  
b. The pVHL-HIF axis 
Among its targets for ubiquitination and subsequent degradation are the hypoxia-inducible factors 
1α and 2α (HIF1α and HIF2α), which are involved in the cell response to low oxygen. Under 
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normoxic conditions, HIF1α and 2α are hydroxylated by prolyl hydroxylase 1, 2 and 3 (PHD). 
Prolyl-hydroxylated HIFα is recognized by the VBC complex via the core of the HIFα oxygen-
dependent degradation domain and is targeted for ubiquitination and subsequent proteasomal 
degradation. PHD1, PHD2 and PHD3 are inactive in hypoxic conditions, causing dihydroxylation 
of HIFα and impairing the formation of VBC complex. HIFα then forms a complex with HIFβ 
units that binds  hypoxia-response elements (HRE) (Figure 4), leading to upregulation of many 
genes, such as VEGF, PDGF, EPO, CAIX and CXCR4, which proteins are known to be important 
in angiogenesis and other metastatic processes  [18, 19]. In ccRCC, pVHL deficiency impairs the 
VBC complex assembly, HIFα is then stabilized, its accumulation reflects pseudo-hypoxic 
conditions and triggers the activation of several pro-oncogenic genes involved in angiogenesis, 
pH regulation, glucose transport, invasion, metastasis and glycolysis, in turn leading to the 
“Warburg effect” [20, 21].  
 
Figure 4: pVHL pathway in normoxic and hypoxic conditions  (Gossage et al. [15]). 
Although HIF1α and HIF2α share many transcriptional targets, recent evidences showed that 
HIF1α rather has tumor suppression properties, and HIF2α  is considered as an oncoprotein [18].  
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Loss of chromosomal arm 14q, where HIF1α is located, was shown to be associated with worse 
outcome in ccRCC patients compared to loss of 3p, where VHL is located [22, 23]. In xenograft 
experiments, HIF2α promoted tumor growth whereas HIF1α attenuated tumor growth [24]. 
c. VHL as prognostic and predictive factor 
To date, no consensus exists regarding the use of VHL as a prognostic or predictive biomarker in 
ccRCC [25-30]. Generally, no correlation was found between presence/absence or type of VHL 
mutations and pathological parameters, overall and disease-free survival. Some studies reported 
that the alteration of VHL (mutation or hypermethylation) is even associated with a better 
outcome [31].  
d. VHL inactivation and mutation classification 
VHL has been shown to be affected in more than 90% of the ccRCC cases, either by allelic 
deletion, promoter methylation (20%), or mutations (70-80%) [29, 32]. The inactivation of VHL 
has been found to be a critical point in the initiation of tumor formation and is the major aspect of 
this study in the context of ccRCC [33-35]. In the particular case of VHL disease, a syndrome 
caused by genetic mutations of VHL,  individuals inherit a defective allele of VHL and the 
remaining wild-type allele becomes inactivated or lost [36]. This disease is characterized by the 
formation of multiple tumors and cysts such as hemangioblastomas, pheochromocytomas and 
ccRCC. In this disease, mutations are classified depending on their type: frameshift and nonsense 
mutations that most likely abrogate pVHL functions (type 1 disease), and missense mutations 
whose effects can range from no or little impact to high destabilization of pVHL (type 2 disease). 
Type 2 VHL disease can be further divided into type 2A with a low risk of developing ccRCC, 
type 2B with a high risk of ccRCC and type 2C with an increased risk of pheochromocytoma 
[37].  
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e. VHL missense mutations 
Although it has been shown that patients presenting loss-of-function (LOF) mutations in VHL 
may have a poorer prognosis compared to wild-type or missense [30], little is known about the 
effects of missense mutations on pVHL functions. Evidence of mutant VHL expression at the 
RNA level [38, 39] as well as at the protein level [40, 41] were described in other studies. 
Although pVHL mutant forms tend to rapidly degrade, they still may exhibit partial function 
[42]. In sporadic ccRCC, Rechsteiner et al. proposed a functional classification of missense 
mutations in three groups: A: mutations leading to a severe destabilization of pVHL; B: 
mutations with no destabilizing effects on pVHL but impaired interaction with HIF1α, elongin B, 
and elongin C; and C: mutations leading to protein behaving like the wild-type (WT) protein 
[43]. VHL LOF mutations (frameshift, nonsense and splice site mutations) highly likely abrogate 
pVHL function, whereas the consequences of missense mutations on pVHL stability and 
interactors binding ability are rather unclear. Indeed, missense mutations may provoke diverse 
effects on pVHL interactions with binding partners, thus exerting different impact on pathways 
normally regulated by pVHL. This was shown for HIF1α and HIF2α degradation [43] as well as 
for other pVHL binding partners including Jade1, RPB1, VDU1, EEF1α1 and CCT-ζ-2 for which 
loss of binding capability upon missense mutations was demonstrated [44-49]. One part of this 
project was a detailed analysis of the VHL missense mutation spectrum, their effects on pVHL 
stability and the potential pVHL interactor binding domains affected. 
f. pVHL acts as a multiadaptor protein 
The pVHL structure is divided in two major binding regions. The β-sheet is known to bare the 
HIF1/2α binding domains and the α-helical domain is responsible for EloB/C interaction. 
Additionally, pVHL has been identified as a multiadaptor protein and Leonardi et al. reviewed 35 
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experimentally verified proteins interacting with pVHL with their putative binding regions 
(Figure 5) [50-53]. In addition to HIF1/2α degradation, pVHL is also involved in the recruitment 
of many effector proteins to regulate a variety of cellular processes including microtubule 
stability, activation of p53, neuronal apoptosis, cellular senescence and aneuploidy, 
ubiquitination of RNA polymerase II and regulation of NF-κB activity [54].  
 
Figure 5:  VHL gene and  pVHL structure, and protein-protein interaction sites Adapted from 
Richards et al. [55] and Leonardi et al. [50] 
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E. ccRCC treatment strategies 
The different treatments strategies for ccRCC are partial or total nephrectomy, radiation and 
chemotherapy (which is rather unusual because ccRCC is often resistant to these therapies), and 
targeted therapy. Treatments currently used in the clinics for metastatic disease are mostly anti-
angiogenic tyrosine-kinase inhibitors that target VEGFR and PDGFR to counter the upregulation 
of HIFs caused by inactivation of VHL, and drugs targeting the mTOR pathway which is a critical 
regulator of cell growth. Those treatments are currently the gold standard for treating ccRCC but 
despite all the recent efforts towards finding efficient therapies they remain suboptimal for most 
metastatic ccRCC [1]. Sunitinib is the most often used drug with only 31% of mainly partial 
response [56]. 
F. p53 
a. Gene, function, pathways 
The human tumor suppressor protein p53 is encoded by the TP53 gene located at the locus 
17p13.1 in the genome. This protein contains domains for transcriptional activation, DNA 
binding, and oligomerization, as the protein can associate in tetramers. p53 activation leads to cell 
cycle arrest, DNA repair and apoptosis. p53 degradation is mediated by a ubiquitin ligase, Mdm2, 
that binds and targets p53 for its proteasomal degradation. p53 activation and stabilization is very 
complex and is driven by several mechanisms (reviewed by Lavin et al. [57]). Post-translational 
modifications such as phosphorylation (i.e. by ATM, AMPK and JNK), acetylation (i.e. by 
p300), methylation, ubiquitination and sumoylation occur in more than 20 different sites of p53, 
leading to its activation. Cellular stresses such as UV light, DNA damage, hypoxia or response to 
cytokine stimulation, cell-cell contact, viruses and other metabolic changes also activate p53. 
Other pathways of p53 activation involve the inhibition of Mdm2 (i.e. through PTEN or p19). 
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p53 stabilization and activation leads to transactivation of its downstream target genes such as 
p21, Bax and Noxa (Figure 6) [58]. The transcriptional activation of these downstream targets can 
induce cell cycle arrest, apoptosis, senescence, DNA repair, or metabolic changes. In contrast, 
p53 inactivation promotes tumor progression. Many human cancers have mutations in p53 which 
is the most frequently mutated gene in cancer [59-61]. 
 
Figure 6:  p53 pathway. Adapted from Brown et al. [62] 
b. p53, pVHL and HIF 
The role of p53 in ccRCC and its relation to pVHL is yet unclear. Whereas one research group 
concluded that p53 expression was not pVHL-dependent [63], others showed that pVHL can 
associate directly to p53, leading to p53 stabilization and enhancement of its transcriptional 
activity [64-66]. As an indirect stabilizing effect , Roe et al. suggested the suppression of Mdm2-
mediated ubiquitination of p53 by pVHL [67]. pVHL inactivation in RCC cells have been proven 
to lead to decreased apoptosis [67], which may be explained in part by the lack of 
phosphorylation of pVHL by checkpoint-kinase 2, impairing the recruitment of p53 coactivators 
(such as p300 and Tip60) [65]. The loss of VHL has also been demonstrated to lead to p53 
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inactivation through progerin expression [68]. Moreover, recent findings suggest complex 
regulation between p53 and HIFs. Indeed, p53 has been described to bind HIF1α [69] which will 
affect its stability and activity [70]. Since p300 is a co-activator of both p53 and HIF1α [71], p53 
may regulate HIF1α by a competition mechanism leading to a downregulation of HIF1α signaling 
[72]. Additionally, HIF2α accumulation could lead to p53 suppression [73] and its inhibition to 
p53 activity enhancement [74].  
c. p53 in ccRCC 
Previous studies showed that p53 was immunohistochemically 4 to 5 times less expressed in 
ccRCC than in other RCC subtypes [75]. Seventy percent of papillary, 27% of chromophobe, and 
only 12% of ccRCC cases overexpressed p53. There was no association with stage and grade of 
the tumor [76]. In a previous study, p53 overexpression in 50 clear cell RCC cases was associated 
with rapid proliferation and was linked to poor prognosis [77]. In contrast to many other cancer 
types where p53 is one of the most frequently mutated genes [78], p53 mutations are rare in 
ccRCC [79-81]. Like tumors with p53 mutations, ccRCC is also known to be associated with 
chemoresistance [82]. Gurova et al. suggested that p53 signaling in this tumor type might be 
repressed by some other mechanisms independent of p53 mutations [83], such as constitutive 
activation of NF-kB [84]. More recently, the multi-domain ubiquitin E3 ligase UHRF1 has been 
proposed as a suppressor of p53 pathway activation and p53-dependent apoptosis in ccRCC [85]. 
The downregulation of TRIM8, another E3 ubiquitin ligase, has also been shown to suppress p53 
activity in ccRCC [86] but there is to date no consensus on p53 signaling downregulation in 
ccRCC. Interestingly, p21, a p53 downstream target responsible of cell-cycle arrest, has been 
shown to be a possible prognostic factor for ccRCC patients for localized disease, its 
overexpression leading to a decreased risk of death due to ccRCC [87, 88].  
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d. p53 and therapy 
Cancer cell resistance is often related to p53 pathway. Although p53 in ccRCC is wild-type in the 
vast majority of the cases, ccRCC is resistant to chemotherapy and can be intrinsically resistant 
or acquire resistance to anti-angiogenic therapies [89].  
Recently, it has also been shown that Sunitinib can increase p53 activity through inhibition of 
NF-κB for cell senescence in metastatic RCC [90] and that loss of p53 lead to a decrease of anti-
angiogenic therapy efficiency in colorectal cancer [91].  
Camptothecin (CPT), a specific inhibitor of DNA topoisomerase I that activates p53 for apoptosis 
through DNA damage, has been shown in other studies to trigger enhanced apoptosis in the 
presence of pVHL. CPT has been tested in preclinical and clinical trials in breast cancer and 
ovarian cancer with promising effects by enhancing apoptosis and downregulating HIF1/2α, 
alone or in combination with bevacizumab. This drug is currently studied in clinical trial phase II 
for metastatic RCC [92-94]. 
G. Other genes frequently mutated in ccRCC 
Although VHL alterations are by far the most prominent ones in ccRCC, impaired pVHL 
functions are not always sufficient for tumor formation and proliferation and VHL inactivation 
alone cannot explain ccRCC development [95, 96]. Several other frequently mutated genes have 
been identified in this disease, such as PBRM1, BAP1 and SETD2 [97, 98]. All 3 genes are 
located on the short arm of chromosome 3, which is frequently lost in ccRCC, and have 
chromatin-remodeling functions. PBRM1 protein is functionally regulated by p53-induced 
protein degradation in renal cell carcinomas and PBRM1 showed truncating mutations in more 
than 30% of ccRCC cases in previous studies [97, 99, 100]. SETD2 is required for DNA double-
strand break repair and activation of p53 and a 15% mutation rate of its encoding gene was 
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reported [97, 101, 102]. BAP1 is a protein involved in chromatin remodeling and transcriptional 
regulation and has been found mutated in up to 15% of the cases [97, 103, 104]. Other genes 
involved in chromatin modification and MTOR pathway such as KDM5C, KDM6A, MTOR, 
TSC1 and PTEN are also altered in about 20% of ccRCCs [105, 106]. 
This intratumoral heterogeneity in ccRCC can lead to different treatment responses from different 
cell populations [107]. This feature is particularly important and a proper mutation landscape 
overview of these genes could be used for selecting appropriate targeted therapies [54]. A recent 
review published by Wei et al. proposed a “river model” for illustrating the events leading to 
tumor formation in ccRCC. In this model, VHL is considered as a first hit initiating the tumor, 
PBRM1 alteration as a second hit, and SETD2 and TSC1 mutations would appear in a later stage. 
This group also described a “window of opportunity” when the hallmarks of cancer are already 
acquired and after which targeted therapies could have a limited efficiency due to treatment 
resistance caused by additional genetic alterations (Figure 7) [108].  
 
Figure 7: The braided river model of convergent cancer evolution from Wei et al. [108] 
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II. Objectives  
In this thesis, we intended to investigate more closely the VHL missense mutations spectrum to 
determine the most frequently affected binding domains of pVHL, and their potential impact on 
pVHL function and on response to treatment. We hypothesized that missense mutations exert 
different impact on the binding capability of pVHL targets and its pathways which may lead to 
diverse tumor aggressiveness.  
In the first part of the project, we investigated the VHL mutation status in a cohort of 360 patients 
with sporadic ccRCC. We particularly focused on missense mutations and their potential 
biological effects on the pathways regulated by pVHL’s interactors and studied their association 
with clinical follow-up of 30 patients treated with tyrosine-kinase inhibitors (TKI). 
In the second part, we specifically focused on the VHL missense mutations occurring in the 
p53/EloC binding domain region and their functional effects on protein stability, HIF 
degradation, p53 signaling and cell behavior towards proliferation and apoptosis. We 
hypothesized that VHL missense mutations occurring in the p53 binding domain of pVHL can 
lead to a deficiency in p53 transactivation and/or promote HIF1α and HIF2α accumulation, thus 
impacting tumor development and possibly therapy efficiency. In this study, we investigated 4 
different missense mutations located in the p53 binding site (codons 154-163), which is 
overlapping with the ElonginC binding domain (codons 157-171). Due to this overlap, the 
missense mutations investigated could have an impact on p53 signaling and/or on HIF 
degradation through an altered binding to ElonginC. We also investigated their influence on cells 
behavior under treatment with chemotherapy or TKI.  
Finally, we used next-generation sequencing on DNA samples from the 30 ccRCC patients with 
follow-up data after treatment. The goal was to unravel possible variant clusters that could be 
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associated with tumor regression among more than 400 cancer-related genes. We focused 
particularly on a set of 18 genes: VHL, BAP1, HIF1a, PDGFRA, PDGF(R)B, TP53, CARD11, 
NFkB, TSC1, MTOR, EGFR, PBRM1, SETD2, KDM5C, KDM6A, PTEN and PIK3CA, all of 
which have been reported to be mutated in ccRCC. 
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III. Characterization of VHL missense mutations in sporadic clear 
cell renal cell carcinoma: hotspots, affected binding domains, 
functional impact on pVHL and therapeutic relevance 
In the following part, we studied the distribution and impact of the 89 missense mutations found 
in our cohort of 360 ccRCC cases and determined the pathways potentially affected by the 
resulting protein alterations. 
A. Abstract 
Background:  The VHL protein (pVHL) is a multiadaptor protein that interacts with more than 
30 different binding partners involved in many oncogenic processes. About 70% of clear cell 
renal cell carcinoma (ccRCC) have VHL mutations with varying impact on pVHL function. Loss 
of pVHL function leads to the accumulation of Hypoxia Inducible Factor (HIF), which is targeted 
by current targeted treatments. In contrast to nonsense and frameshift mutations that highly likely 
nullify pVHL multipurpose functions, missense mutations may rather specifically influence the 
binding capability of pVHL to its partners. The affected pathways may offer predictive clues to 
therapy and response to treatment. In this study, we focused on the VHL missense mutation 
pattern in ccRCC, and studied their potential effects on pVHL protein stability and binding 
partners and discussed treatment options.  
Methods: We sequenced VHL in 360 sporadic ccRCC FFPE samples and compared observed 
and expected frequency of missense mutations in 32 different binding domains. The prediction of 
the impact of those mutations on protein stability and function was assessed in silico. The 
response to HIF-related, anti-angiogenic treatment of 30 patients with known VHL mutation 
status was also investigated. 
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Results: We identified 254 VHL mutations (68.3% of the cases) including 89 missense mutations 
(35%). Codons Ser65, Asn78, Ser80, Trp117 and Leu184 represented hotspots and missense 
mutations in Trp117 and Leu 184 were predicted to highly destabilize pVHL. About 40% of VHL 
missense mutations were predicted to cause severe protein malfunction. The pVHL binding 
domains for HIF1αN, BCL2L11, HIF1/2α, RPB1, PRKCZ, aPKC-λ/ι, EEF1α1, CCT-ζ-2, and 
Cullin2 were preferentially affected. These binding partners are mainly acting in transcriptional 
regulation, apoptosis and ubiquitin ligation. There was no correlation between VHL mutation 
status and response to treatment. 
Conclusions: VHL missense mutations may exert mild, moderate or strong impact on pVHL 
stability. Besides the HIF binding domain, other pVHL binding sites seem to be non-randomly 
altered by missense mutations. In contrast to LOF mutations that affect all the different pathways 
normally controlled by pVHL, missense mutations may be rather appropriate for designing tailor-
made treatment strategies for ccRCC. 
Keywords: clear cell renal cell carcinoma, VHL, missense mutations, binding domains, pVHL 
stability, therapy 
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B. Results 
a. VHL mutation types, mutation sites, tumor stage and grade distribution 
Two hundred forty-six of 360 (68.3%) sequenced ccRCC were mutated. Eight of these tumors 
had two mutations. The frequencies of the VHL mutation types are illustrated in Figure 8.  
 
 
 
 
 
 
 
 
 
Figure 8: VHL mutation types 
Since deletions, insertions, splice site mutations and nonsense mutations most likely abrogate 
most if not all pVHL functions, they were referred to as loss of function (LOF) mutations. An 
overview of VHL LOF and missense mutation sites in the pVHL sequence and the affected 
binding domains of pVHL’s interactors are shown in Figure 9. 
 
 
360 cases 
246 tumors mutated 
(68.3%) 
254 mutations (8 
double) 
116 deletions/insertions 
(45.7%) 
99 frameshift (85.3%) 
17 in frame (14.7%) 
18 splice site mutations 
(7.1%) 
120 point mutations 
(47.2%) 
1 silent mutation 
30 nonsense mutations 
(25%) 
89 missense mutations 
(75%) 
114 wild-type (31.7%) 
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Figure 9: VHL mutations sites 
VHL mutation frequencies were similar in organ-confined pT1/2 and metastasizing pT3/4 
ccRCC. There was no correlation between the number of mutations and stage or grade (Table 4).  
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Table 4: Tumor stage, Fuhrman grade and type of VHL mutations in 346 ccRCC patients. 
 
Tumor stage or grade information was not available for 14 patients.  
Detailed information of the 256 mutations is given in supplementary table 1 (see Annex). 
b. VHL mutation hotspots 
A closer look at the mutation sites within the protein revealed that some codons were more 
frequently mutated than others. Fourteen mutations (5.5%) were located at Ser65, nine (3.5%) at 
Trp117, 8 (3.1%) at Phe76, 7 (2.8% each) at Asn78, Ser80, Leu135, and Arg161, 6 (2.4%) at 
His115, and 5 mutations were at Gly114 and Leu184 (2% each).  
The codons that were most often affected by missense mutations were Ser65, Asn78, Ser80 (six 
mutations each, 6.7%), Trp117 and Leu184 (five mutations each, 5.6%). Codons Phe76 and 
Leu135 showed only LOF mutations. 
c. Preferentially affected binding domains of pVHL interactors 
We next assigned 88 of 89 missense mutations to the putative binding domains of 32 pVHL 
interactors. One missense mutation in the stop codon was excluded from this analysis. As 
expected, large binding domains of interacting partners covering more than 60 amino acids of 
pVHL showed relative high frequencies of mutations. Between 44% and 100% of the missense 
mutations were located in the VHLAK (100%), HIF1αN (77.3%), BCL2L11 (70.5%), RPB1 
(60.2%), and RPB7 (44.3%) binding domains. Notably, about half of the missense mutations 
VHL status 1+2 3+4 1+2 3+4
Nonsense 6 (21.4) 22 (78.6) 15 (53.6) 13 (46.4)
Frame shift 43 (44.8) 53 (55.2) 51 (53.1) 45 (46.9)
Missense 21 ( 26.9) 57 (73.1) 45 (56.3) 35 (43.8)
In frame 6 (35.3) 11 (64.7) 6 (37.5) 10 (62.5)
Splice site 3 (20) 12 (80) 9 (56.3) 7 (43.8)
Wild-type 37 (33) 75 (67) 52 (47.3) 58 (52.7)
Fuhrman n (%) Tumor stage (pT) n (%)
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(45/88, 51.1%) resided in the HIF1α and HIF2α (EPAS1) binding domain comprising 51 amino 
acids. 
Between 20-35% of the missense mutations were located in the binding domains of PRKCD, 
VDU1/2, PRKCZ, EEF1α1, Nur77 and CARD9 (25-60 amino acids). The frequencies of 
missense mutations found in the smaller binding domains (9-28 amino acids) of JADE1, SP1, 
KIF3A, TUBA4A, HuR, aPKC-λ/ι, TBP1, CCT-ζ-2, EloC and p53 ranged between 8 and 23%. 
All interactors, related pathways and binding domains affected by mutations are listed in Table 5. 
Missense mutations which preferentially affected binding domains were identified by comparing 
the observed number with the expected number of mutation and by normalizing for each binding 
domain based on their amino acid length. As the first 54 amino acids of pVHL were not covered 
by Sanger sequencing, the expected number of missense mutation per codon was 0.55. 
We found that the binding domains showing significantly higher rates of missense mutations as 
expected were for pVHL interactors HIF1αN, BCL2L11, HIF1α, HIF2α, RPB1, PRKCZ, aPKC-
λ/ι, EEF1α1, CCT-ζ-2, and Cullin2. pVHL binding partners with involved pathways and the ratio 
of observed versus expected frequency of missense mutations are shown in Table 5. Additional 
information on pVHL binding partners is given in supplementary S1 (see Annex). 
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Table 5: List of interactors and binding domains, number of missense mutations, comparison 
observed/expected frequency, and pathway affected. 
Name of the 
interactor pVHL AA involved 
Missense 
mutations 
count N (%) 
Frequency of 
observed 
missense 
mutations 
compared to 
expected 
p-value Pathway of the interactor 
CK2 S33, S38, S43 0 (0) lower ns Protein amino acid phosphorylation 
GSK3 S68 1 (1.1) 1.8X higher ns Wnt signaling pathway 
CK1 S72 1 (1.1) 1.8X higher ns Wnt signaling pathway 
NEDD8 K159 1 (1.1) 1.8X higher ns Ubl conjugation pathway 
KIFAP3 1-54 0 (0) lower ns Microtubule-based movement 
HIF1αN 1-155 68 (77.3) 1.2X higher ** HIF1α pathway 
VDU1/USP33 54-83 22 (25) 1.3X higher ns Ubl conjugation pathway 
VDU2/USP20 54-83 22 (25) 1.3X higher ns Ubl conjugation pathway 
RPB7 54-113 39 (44.3) 1.2X higher ns Regulatory RNA pathways 
VHLAK 54-213 88 (100) equal not applicable Apoptosis 
BCL2L11 55-143 62 (70.5) 1.3X higher ** Apoptosis 
HIF1α 67-117 45 (51.1) 1.6X higher *** Hif1_tf pathway 
EPAS1 (HIF2α) 67-117 45 (51.1) 1.6X higher *** Vegfr1_2 pathway 
RPB1 60-120 53 (60.2) 1.6X higher *** Regulatory RNA pathways 
PRKCZ 87-122 30 (34.1) 1.5X higher ** Antiapoptosis, intracellular Signaling 
CARD9 92-121 22 (25) 1.3X higher ns NFKB and MAPK signalling 
TUBA4A 95-123 20 (22.7) 1.3X higher ns MT stabilization and dynamic cell polarity 
KIF3A 95-123 20 (22.7) 1.3X higher ns Hedgehog_gli pathway 
SP1 96-122 20 (22.7) 1.3X higher ns TGF-beta signaling pathway 
JADE1 96-122 20 (22.7) 1.3X higher ns Apoptosis 
PRKCD 113-122, 130-154 26 (29.5) 1.4X higher ns Regulation of receptor activity, senescence 
aPKC-λ/ι 114-122 16 (18.2) 3.2X higher *** Signalling by NGF 
EEF1α1 114-138 23 (26.1) 1.7X higher ** Protein biosynthesis 
CCT-ζ-2 116-119, 148-155 13 (14.8) 2X higher ** Chaperone-mediated protein complex assembly 
TBP1 136-154 7 (8) 1.5X lower ns Signaling by Wnt, DNA Replication, Apoptosis 
p53 154-163 8 (9.1) 1.5X higher ns Apoptosis 
Nur77 155-213 20 (22.7) 1.6X lower ** MAPK and NGF signaling pathways 
EloC 157-171 11 (12.5) 1.3X higher ns Ubl conjugation pathway 
HuR (RNA binding protein) 157-184 19 (21.6) 1.2X higher ns mRNA stabilization 
EloB 170-174 1 (1.1) 2.8X lower ns Ubl conjugation pathway 
Cullin2 181-184 6 (6.8) 2.7X higher ** Ubl conjugation pathway 
VBP1 187-213 1 (1.1) 14.9X lower *** Morphogenesis 
14 splice site mutations and a frameshift mutation for which the position of the affected amino 
acid cannot be determined and the missense mutation c.642 A>C/ p.X214Cys are excluded from 
this table. p-value summary: P-value: *<0.05, **<0.01, ***<0.001, ns "not significant" 
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d. VHL missense mutations and pVHL stability 
Eighty-eight missense mutations were analyzed in silico using the program SDM to determine the 
protein thermodynamic change (ddG) triggered by those mutations. In this context, ddG is an 
indicator of pVHL stability and suggests whether or not a missense mutation causes deleterious 
functional impact and is associated with disease. 
A large proportion of the VHL missense mutations (60/88, 68%) were predicted to destabilize the 
resulting protein (ddG<-0.5), eleven mutations (11/88, 12.5%) had a neutral effect  
(-0.5<ddG<0.5), and seventeen had a stabilizing effect (17/88, 19.3%) on pVHL. Thirty-three of 
88 (37.5%) missense mutations were  highly destabilizing and only 2 (2.3%), were  highly 
stabilizing, suggesting that about 40% of  VHL missense mutations were predicted to cause 
protein malfunction (ddG<-2 and ddG>2 respectively). VHL missense mutations and their 
predicted effects on pVHL stability and association with disease are listed in supplementary table 
2 (see Annex).  
By focusing on the  HIF1/2α binding domain (amino acids 67-117) and the remaining parts of the 
protein (amino acids 54-66, 118-213) we observed significantly more missense mutations in the 
HIF1/2α binding domain than expected (43/88 observed, 28/88 expected (p-value <0.0001). 
However, the frequency of destabilizing mutations (ddG<-0.5) in the HIF1/2α binding domain 
(32/45, 71.1%) was similar to that seen for the remaining parts of the protein (28/43, 65.1%).  
 Notably, all of the hotspot missense mutations found in codons Trp117 and Leu184 were 
destabilizing and 3 out of 5 and 5 out of 5 mutations, respectively, were predicted to cause 
protein malfunction. In addition, all missense mutations in codon Ser80 destabilize pVHL, codon 
Ser65 had 3 destabilizing and 3 stabilizing mutations, and codon Ser65 had 2 destabilizing and 4 
stabilizing mutations. The sites of all missense mutations are shown together with their stability 
prediction in Figure 10. 
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Figure 10:  Distribution of VHL missense mutations and their predicted stability. A: destabilizing; 
B: neutral and stabilizing mutations 
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e. pVHL mutations and treatment response 
After surgical resection of the primary tumor, 30 patients from the cohort were treated with anti-
angiogenic drugs that are currently used in clinics for patients with metastatic ccRCC. These 
patients were subdivided into three groups according to response to therapy: progressive, stable 
and regressive disease. Treatment administered, response, VHL mutation status, tumor stage and 
grade are listed in Table 6. The proportion of responders (stable + regressive disease) was 52.6% 
for the LOF (10/19), 33.3% for the missense mutations (2/6), and 40% for the wild-type VHL 
(2/5).  
There was no correlation between disease progression status, tumor stage, grade and the mutation 
consequences for the function of pVHL. 
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Table 6: Treatment, response, and VHL mutation status of the patients treated with anti-
angiogenic therapies. 
Mutation Mutation consequence 
Functionality 
prediction Interacting partners 
Disease 
progression 
status 
Treatment pT stage 
Fuhrman 
grade 
c.163delG/p.Glu55ArgfsX11 fs LOF  PD Pazopanib>Everolimus 3 3 
c172delC/p.Arg58GlyfsX9 fs LOF  PD IFNa>Pazopanib   
c.194C>T/p.Ser65Leu missense stabilizing HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/RPB1 PD Sunitinib   
c.240T>A/p.Ser80Arg missense destabilizing 
HIF1αN/VDU1/USP33/VDU2/USP20/
RPB7/VHLAK/BCL2L11/HIF1α/EPA
S1/RPB1 
PD IFNa>Sorafenib 1  
c. 262T>A/p.Trp88Arg missense highly destabilizing 
HIF1αN/RPB7/VHLAK/BCL2L11/HIF
1α/EPAS1/RPB1/PRKCZ PD Sunitinib 3 3 
c.268_273del/p.Asn90_Phe9
1del in frame LOF  PD Sunitinib  3 
c.IVS1+1G>A (c.340+1G>A) splice mut LOF  PD 
Sorafenib>Sunitinib 
>Everolimus   
c.345_364del/p.Leu116Argfs
X9 fs LOF  PD IFNa>Sorafenib   
c.349delT/p.Trp117GlyfsX42 fs LOF  PD Sunitinib 3 3 
c.484T>C/p.Cys162Arg missense neutral VHLAK/p53/Nur77/EloC/HuR PD Sunitinib>Sorafenib >Everolimus>Pazopanib 3 3 
c.497_505del9/p.Arg167Vald
elSerLeu in frame LOF  PD Sunitinib 3 3 
C.580_583delinsAA/p.Val194
LysfsX61 fs LOF  PD Sunitinib>Sorafenib   
c.586A>T/p.Lys196X nonsense LOF  PD 
Sunitinib>Sorafenib 
>Everolimus 1  
 wild-type wild-type  PD Pazopanib 3 4 
 wild-type wild-type  PD 
Sunitinib>Pazopanib 
>Sorafenib>Everolimus 4 3 
 wild-type wild-type  PD Sunitinib 2 3 
c.161_162delTG/p.Met54Argf
sX77 fs LOF  SD Sunitinib 3 4 
c.203C>A/p.Ser68X nonsense LOF  SD 
Sorafenib>Pazopanib 
>Everolimus 3 4 
c.327insA/p.His110ProfsX22 fs LOF  SD Sunitinib>Sorafenib 1 4 
c.IVS1+2T>A (c.340+2T>A) splice mut LOF  SD Pazopanib>Axitinib 3 3 
c.345insC/p.Leu116ProfsX15 fs LOF  SD 
Bevacizumab>IFNa 
>Pazopanib 3 4 
c.350delG/p.Trp117CysfsX42 fs LOF  SD IFNa/Bevacizumab 1 3 
c.481C>T/p.Arg161X nonsense LOF  SD Sorafenib 2 2 
 wild-type wild-type  SD 
Sunitinib>Sorafenib 
>Everolimus   
c.167_168delCC/p.Ala56Glyf
sX75 fs LOF  RD Sorafenib 3 1 
c.227_229del3/p.Phe76del in frame LOF  RD Pazopanib>Sunitinib 1 3 
c.340G>T/p.Gly114Cys missense neutral 
HIF1αN/VHLAK/BCL2L11/HIF1α/EP
AS1/RPB1/PRKCZ/CARD9/TUBA4A
/KIF3A/SP1/JADE1/PRKCD/aPKC-
λ/ι/EEF1α1 
RD IFNa>Bevacizumab 2 3 
c.383T>C/p.Leu128Pro * missense higly destabilizing HIF1αN/VHLAK/BCL2L11/EEF1α1 RD Pazopanib 3 4 
c.430G>T/p.Gly144X * nonsense LOF  RD Pazopanib 3 4 
c.458T>C/p.Leu153Pro missense destabilizing HIF1αN/VHLAK/PRKCD/CCT-ζ-2/TBP1 RD Sunitinib 2 3 
 wild-type wild-type  RD Pazopanib>Everolimus 3 3 
PD: progressive disease; SD: Stable disease; RD: Regressive disease; LOF: loss-of-function; fs: 
frameshift. * one patient with two mutations 
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C. Discussion 
It is widely accepted that in almost all ccRCC both VHL alleles are inactivated by chromosome 
3p loss, mutation and hypermethylation [15, 29, 32]. In contrast to frameshifts, nonsense codons 
and alteration of splice sites, which highly likely cause loss of function of pVHL in about 50% of 
these tumors, the consequences of VHL missense mutations present in 25% may significantly 
vary. A detailed and comprehensive investigation of such mutations in this context can hardly be 
found in the literature. The goal of our study was therefore to sequence the VHL tumor suppressor 
gene in 360 ccRCC patients and characterize missense mutations by focusing on preferentially 
affected sites in the gene and their potential consequences on pVHL function and its binding 
partners.  
The frequency of VHL mutations found in about 70% of the patients was comparable to 
previously published data [34, 109]. There was no correlation with VHL mutation types and the 
prognostic parameters tumor stage and grade, which is consistent with previous studies [27, 34, 
110]. Although most of the VHL mutations were private, we found several hotspot mutations in 
our cohort. Between 5 and 14 mutations  affected codons Ser65, Phe76, Asn78, Ser80, Gly114, 
His115, Trp117, Leu135, Arg161 and Leu184. Interestingly, approximately one third of the 88 
missense mutations occurred at codons Ser65, Asn78, Ser80, Trp117 and Leu184 (5-6 mutations 
per codon). Those missense mutations have already been described in the VHL mutations 
database-UMD [111] and in the COSMIC database for ccRCC [81] where they represent about 
10% of all VHL mutations. This frequency is consistent with our finding (28/256, 10.9%) and 
confirms the quality of the sequencing data obtained from our patient cohort.  
In addition to the hotspot missense mutations, we also noticed considerable discrepancies 
between the expected and observed number of missense mutations which particularly affected the 
binding domains of 10 of 32 pVHL targets. Significant more missense mutations than expected 
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were seen in binding domains specific for HIF1αN, BCL2L11, HIF1α, HIF2α, RPB1, PRKCZ, 
aPKC-λ/ι, EEF1α1, CCT-ζ-2, and Cullin2. Apart from HIFα, most of these proteins are mainly 
involved in apoptosis (BCL2L11, aPKC-λ/ι), transcriptional regulation (RPB1, PRKCZ) and 
ubiquitin ligation (CCT-ζ-2, Cullin2). Some of these missense mutations may exert pleiotropic 
effects on different pathways. This was recently shown with the mutants Phe81Ser and 
Arg167Gln which cause partial abrogation of VBC complex interactions and fail to downregulate 
HIF1/2α. Simultaneously, they also lead to enhanced anti-apoptosis signaling and weaken the 
assembly of RNA Polymerase II complex and protein ubiquitination signaling pathway [112]. 
Notably, the binding sites for aPKC-λ/ι, CCT-ζ-2, and Cullin2 were the most affected ones and 
may thus represent potential drug targets alternatively to HIF. For example, disruption of pVHL 
binding leads to subsequent ubiquitination of aPKC-λ/ι, which in turn deregulates JunB 
expression and promotes tumor progression in VHL disease-related pheochromocytoma. 
Uncontrolled expression of JunB may also be important in ccRCC as JunB was found to be 
upregulated in sporadic, pVHL inactivated, ccRCC [113, 114]. Moreover, VHL mutations were 
shown to impair the interaction with pVHL and CCT-ζ-2 which, consequently, caused improper 
folding of the VBC complex [49, 115]. Given the function of Cullin2 a default in VBC complex 
formation may also be expected from disrupted binding of pVHL with this protein. Interestingly, 
the binding domain for VBP1 located at the 3’ end of VHL exon 3 seems to be spared from 
mutations. VBP1 functions as a chaperone protein and may play a role in the transport of pVHL 
from the perinuclear granules to the nucleus or cytoplasm [116]. The strikingly low frequency of 
mutations (15 times lower than expected) in this region of VHL may reflect the importance of 
sustaining accurate pVHL trafficking in ccRCC. This is supported by a previous report showing 
that ccRCC with pVHL expression in both nuclear and cytoplasmic compartments had a better 
prognosis [40].  
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The effects of missense mutations on protein stability were determined in silico by calculating the 
thermodynamic change caused by one missense mutation. The tool for determining protein 
stability was proven powerful with mutations predicted to be highly destabilizing leading to both 
faster degradation of pVHL and stabilization of HIF1/2α [43]. Based on this observation it is 
conceivable that those mutations are critical for most if not all binding partners of pVHL. 
In addition to their potential influence on pVHL function we also attempted to further 
characterize the 88 missense mutations with regard to their tumorigenic potential. We used the 
Symphony classification system that allows subclassifying VHL missense mutations in VHL 
disease patients according to their risk of developing ccRCC [117]. Among the 88 missense 
mutations, 61 (80%) were classified by Symphony as high risk of developing ccRCC. We 
conclude that most of the missense mutations, even those with neutral or mild impact on pVHL 
stability as predicted by SDM, may have strong tumorigenic potential. Notably, only two of the 
remaining 17 missense mutations were highly destabilizing mutations (Ile151Ser and His115Leu) 
and classified as low risk of ccRCC.  
Current therapeutic strategies for ccRCC focus on Tyrosine Kinase Inhibitors (such as sunitinib, 
sorafenib, pazopanib, axitinib) or other anti-angiogenic drugs (i.e. bevacizumab)  to counteract 
VEGF/ PDGF upregulation in VHL mutated tumors with accumulated HIF1/2α [118]. Treatment 
with Sunitinib as the most commonly used targeted therapy show mainly partial response in 31% 
of the patients with metastatic ccRCC [56]. It is tempting to speculate that the response rate of 
ccRCC patients may be linked to the VHL mutation type present in a tumor. We therefore 
analyzed follow-up data of 30 ccRCC patients with known VHL mutation status who were treated 
with anti-angiogenic drugs. No significant association was seen between VHL mutation status and 
response to treatment in our cohort, although a higher response rate in patients with LOF 
compared to wild-type or missense mutations has been described in a larger study [30]. Fifty-
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three percent of the patients with LOF, 33% with missense mutations, and 40% wild-type 
responded to the treatment (regressive or stable disease). 
D. Conclusions 
In summary, our VHL sequence analysis of 360 ccRCC revealed pVHL binding sites which are 
preferentially altered by missense mutations. In contrast to LOF mutations which probably 
influence most of the pVHL regulated pathways, missense mutations may rather deregulate only 
single or few of those pathways. Moreover, about 15% of ccRCC patients having missense 
mutations with no, mild or only moderate impact on pVHL function even may have fully or at 
least partially functional pVHL. As a consequence, pVHL may retain full ability to degrade 
HIF1/2α but lose its binding ability to other interactors and vice versa. We therefore hypothesize 
that the relatively low response rate to anti-angiogenic drugs may be explained by the 
multipurpose nature of pVHL and the manifold effects on pathways caused by the different 
mutation types (Figure 11). Patients with VHL missense mutation may rather benefit from 
targeted therapies than patients with LOF mutations. For VHL wild-type tumors, other therapy 
modalities aiming at pVHL non-related pathways controlled by tumor suppressors such as 
PBRM1, SETD2 or BAP1 may be more appropriate than the common anti-angiogenic treatment 
[97, 98, 106, 119-124]. 
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Figure 11: Possible treatment strategies according to VHL mutation status 
. 
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IV. Different effects of VHL missense mutations on p53 signaling in 
clear cell renal cell carcinoma 
Although the difference between expected and observed missense mutations located in the p53 or 
in the ElonginC binding domains of pVHL did not reach significance, the overlapping region of 
these two sites (codons 157 to 163) was 2.1 times more often affected by missense mutations than 
what would be expected by chance. This overlapping region is then considered as a preferentially 
affected site. Given the importance of p53 in cancer in general, the low expression of p53 in 
ccRCC and its relation to chemoresistance, we decided in this next part to focus on 4 missense 
mutations which were found at this binding site in our cohort of patients. 
A. Abstract 
Introduction: Clear cell Renal Cell Carcinoma (ccRCC) formation is closely connected to the 
functional loss of the von Hippel-Lindau (VHL) tumor suppressor gene. To date, its best studied 
interaction partners are the subunits of the hypoxia inducible factor (HIF) HIF1α and HIF2α. 
However, recent data identified pVHL as a multifunctional adaptor protein involved in a variety 
of mechanisms, interacting with different binding partners, including p53. p53 is not or low 
expressed in most ccRCC and, unlike in other cancer types, rarely mutated. As nonsense and 
frameshift mutations abrogate most if not all pVHL functions, we propose in this study to 
investigate the impact of VHL missense mutations on p53 expression and transactivation as well 
as the consequences on apoptosis and proliferation with or without treatment. 
Methods: A Tissue Microarray containing 262 ccRCC cores was immunohistochemically stained 
for p53 expression and analyzed regarding their VHL mutation status. Seven RCC4 mutant cell 
lines were engineered, including four missense mutations located in the p53 putative binding 
domain, two affecting HIF binding domain, and one mutation leading to a truncated pVHL. The 
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established cell lines were characterized by Western Blot to assess their effect on pVHL 
expression, HIF degradation and p53 expression as well as by real-time quantitative PCR to 
verify p53’s ability of transactivation on its downstream targets. The cell lines were treated with 
chemotherapeutic drug (Camptothecin) alone or in combination with an anti-angiogenic 
treatment (Sunitinib) and their apoptotic and proliferative behavior were investigated. 
Results: We found that low and absent p53 expression correlated with VHL mutation status and 
severity of the alteration in ccRCC tissue. As expected, HIFα degradation in cell lines was 
dependent on the different VHL mutants. p53 mRNA and its effector targets p21, Bax and Noxa, 
were altered both in cell lines and in tumor tissue. In addition, our results show that VHL 
mutations had an impact on tumor cells’ ability to undergo apoptosis, especially when VHL is 
mutated in the p53 binding domain. No effects were seen on cell proliferation. Both drugs were 
able to efficiently reduce proliferation and Camptothecin additionally increased apoptotic activity 
of the tumor cells. We found no specific pattern of response to Camptothecin or Sunitinib 
although the different VHL mutant forms showed various intensities of responses. We 
hypothesize that response rates in ccRCC patients may be improved with p53-mediating drugs 
which enhance apoptosis. 
Conclusion: Improved understanding of the effects of VHL mutations on pVHL binding partners  
may  lead to the identification of predictive markers for treatment response and, potentially, to 
novel therapeutic strategies. 
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B. Results 
a. p53 expression in ccRCC tumors 
A Tissue Micro-Array (TMA) containing 262 ccRCC, 48 papillary RCC (24 type I, 24 type II), 
22 oncocytoma, 15 chromophobe RCC, 8 from other subtype, and 28 normal tissue cores was 
immunohistochemically stained for p53 expression. Cores with 5 or less nuclei stained were 
grouped into “Low content” category and cores showing at least 6 positive nuclei were grouped 
into “High content”. The details of p53 expression scores are shown in Table 7. 
Table 7: TMA analysis p53 score details 
 
 
TMA analysis showed a low p53 expression in ccRCC, oncocytoma, chromophobe and the 8 
undefined other subtypes similarly to normal tissue. Papillary type I and II showed significantly 
higher content of p53 than ccRCC and normal tissue (Figure 12A). By separating the 262 ccRCC 
in VHL wild-type and VHL mutated tumors, we observed that p53 expression was less frequent in 
tumors with VHL alterations (p-value: 0.0212) (Figure 12B).  We further subdivided mutated 
tumors into those with mild impact (missense mutations predicted to have a milder effect on the 
protein stability and silent mutations), high impact (missense mutations predicted to highly 
destabilize or highly stabilize the protein) and LOF mutations (insertions, deletions, nonsense). 
Normal tissue ccRCC Papillary type I Papillary type II Chromophobe Oncocytoma Other / undefined
0 17 (60.7) 142 (54.2) 5 (20.8) 4 (16.7) 7 (46.7) 7 (31.8) 2 (25)
+1 8 (28.6) 57 (21.8) 5 (20.8) 5 (20.8) 5 (33.3) 6 (27.3) 3 (37.5)
+2 0 (0) 26 (9.9) 5 (20.8) 5 (20.8) 2 (13.3) 7 (31.8) 1 (12.5)
+3 3 (10.7) 37 (14.1) 9 (37.5) 10 (41.7) 1 (6.7) 2 (9.1) 2 (25)
Nuclear score VHL  wt VHL  mutant Mild impact High impact LOF
0 35 (43.2) 107 (59.1) 18 (58.1) 16 (57.1) 73 (59.8)
+1 17 (21) 40 (22.1) 2 (6.5) 5 (17.9) 33 (27
+2 13 (16) 13 (7.2) 4 (12.9) 1 (3.6) 8 (6.6)
+3 16 (19.8) 21 (11.6) 7 (22.6) 6 (21.4) 8 (6.6)
High impact on the protein: highly destabilizing + highly stabilizing mutations
Low impact on the protein: Destabilizing + neutral + stabilizing + silent mutations
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Tumors with wild-type VHL or mild impact mutations showed significantly more frequent p53 
expression compared to tumors with LOF mutations (Figure 12C) whereas high impact mutations 
showed a rate in between mild impact and LOF mutations. 
A                                                                                     B 
 
 
 
 
 
 
 
C 
 
 
 
 
 
Figure 12:  p53 protein expression in A: different tissue types; B: ccRCC according to VHL 
mutation status; and C: ccRCC according to mutation impact on protein stability. Mild impact: 
Destabilizing + neutral + stabilizing + silent mutations; High impact: highly destabilizing + 
highly stabilizing mutations; LOF: Insertions/deletions + nonsense mutations p-values: *<0.05, 
**<0.01, ***<0.001 
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b. Selection of mutations in the p53/EloC binding domains of pVHL 
The binding domains of p53 and EloC are located between codons 154 to 163 and 157 to 171 
respectively [34]. Among 254 mutations found in 360 ccRCC tissue specimen, 25 VHL mutations 
resided in these binding domains and 11 were missense mutations which lead to an amino acid 
change. We used the in silico tool Site Directed Mutator (SDM) 
(http://mordred.bioc.cam.ac.uk/~sdm/links.php) to predict the thermodynamic change upon 
missense mutations and their effects on pVHL. Eight missense mutations were predicted to 
destabilize and 3 missense mutations have no or little impact on pVHL stability.  
For this study, we selected 4 out of the 11 missense mutations occurring in the p53/EloC binding 
domain for further analysis. Three were predicted to have no destabilizing effect on pVHL and to 
remain functional for the HIF degradation pathway (Leu158Val, Arg161Gln, and Cys162Arg) 
and one was predicted to highly destabilize pVHL and to fail to downregulate HIF (Arg161Pro). 
Two other missense mutations occurring in the HIF binding domain, one not affecting and one 
destabilizing pVHL (Tyr98His, Tyr98Asn), and one nonsense mutation located in p53/EloC 
binding domain (Arg161X) were predicted to impair HIF degradation pathway and were used as 
controls.  The mutations selected, the binding domain affected and the predicted effect on 
stability are summarized in Table 8. 
Table 8: List of selected mutations 
 
Babe (Ser65Trp) destabilizing and cause protein malfunction and disease others
VHL30 none none
Leu158Val slightly destabilizing and non disease-associated p53/EloC
Arg161Gln neutral and non disease-associated p53/EloC
Cys162Arg neutral and non-disease-associated p53/EloC
Arg161Pro destabilizing and cause protein malfunction and disease p53/EloC
Tyr98His neutral and non-disease-associated HIF1/2α
Tyr98Asn destabilizing and non-disease-associated HIF1/2α
Arg161X LOF HIF1/2α/p53/EloC
Cell lines stably expressing Predicted effect Binding domain affected
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c. Effects of selected VHL mutations on HIF and p53  
The established stable cell lines were investigated by Western Blot for the effects of the VHL 
missense mutations on HIF degradation and on the two hypoxia markers CAIX and Glut1 (Figure 
13A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: pVHL, p53, HIF1/2α and downstream targets expression in the established stable cell 
lines expressing the selected mutations A: Western Blot; B: HIF reporter assay, HIF 
transcriptional activity of each mutant is compared to VHL30. P-value: *<0.05, **<0.01  
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As expected, pVHL was undetectable in RCC4 Babe and Arg161X. HIF1/2α were upregulated in 
RCC4 Babe, Arg161Pro and Arg161X and also in Cys162Arg which is predicted to be functional 
for HIF degradation. RCC4 Arg161Gln, Tyr98His and Tyr98Asn retained partial functionality 
towards HIF1/2α degradation. The mutant cell line Leu158Val was almost fully functional 
regarding HIF1α destabilization and presented the same pattern as VHL30. CAIX and Glut1 
expression correlated with the HIF1/2α protein levels. No clear difference in p53 expression was 
seen upon the different mutations. 
To further investigate the effect of VHL missense mutations on HIF1/2α signal transduction, we 
performed a HIF reporter assay in the established mutant cell lines.  
When wild-type VHL is overexpressed in RCC4 (VHL30), it leads to a tremendous 
downregulation of the HIF signaling pathway compared to Babe (Figure 13B). HIF 
transcriptional activity is upregulated in Babe, Cys162Arg and Arg161X compared to VHL30 
and at least partially downregulated in Arg161Gln, Tyr98His and Tyr98Asn. Except for mutant 
Leu158Val, results of the HIF reporter assay are comparable to Western Blot analysis. 
d. Impact of VHL mutations on p53 downstream targets 
o In RCC4 stably expressing VHL mutants 
 Previous studies showed that pVHL enhances p53 transcriptional activity and that pVHL with 
Ser111Arg or Ser111Cys missense mutations led to reduced transcription of p53 downstream 
targets compared to pVHL wild-type [19, 23]. Here we studied the effects of the VHL mutations 
stably expressed in our RCC4 cell line on the RNA level of p53 and its effectors p21, Bax and 
Noxa (Figure 14). 
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Figure 14: RNA levels of p53, p21, Bax, Noxa in the established RCC4 stable cell lines. For each 
gene the RNA level of the VHL30 sample was used as reference and compared to the RNA levels 
in the other cell lines; In red, pVHL deficient; in blue, pVHL wild-type; in green, pVHL mutated 
in p53 binding domain; in purple, pVHL mutated in HIF binding domain. P-value: *<0.05, 
**<0.01 
We saw transcription levels of p53, p21 and Noxa in cells expressing the wild-type form of 
pVHL which were higher than in the different mutant forms. All mutant forms caused a decrease 
of p53 RNA level compared to VHL30, although significance was reached only for Babe and 
Arg161Gln. Transcription level of p21 was also reduced in the presence of VHL mutants 
compared to RCC4 expressing VHL wild-type. This discrepancy was significant for 4 mutant 
forms (Babe, Arg161Gln, Cys162Arg and Arg161Pro). All mutant forms of VHL had lower Noxa 
RNA levels than VHL30. Significance was found for Babe, Leu158Val, Arg161Pro, Tyr98Asn 
and the nonsense mutant Arg161X. Bax RNA levels were similar in all the stable cell lines, 
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except for Leu158Val and Arg161Gln showing a lower Bax RNA level than VHL30 expressing 
cells. No significant difference in RNA levels is seen between the 3 mutants in p53 binding 
domain not destabilizing pVHL and the one with destabilizing effects. 
o In ccRCC patients presenting selected VHL mutations 
Three normal kidney tissues and 9 ccRCC tissues (one VHL wild-type, two with mutation 
Leu158Val (#1, #2), one with Arg161Gln, one with Cys162Arg, one with Arg161Pro, one with 
Tyr98Asn and two with Arg161X (#1, #2)) were investigated for RNA expression of VHL, TP53 
and its downstream targets. First, VHL RNA level was assessed in each tissue sample. All but 
tumor tissue with Arg161Gln expressed VHL at least at the same level as the normal tissues 
(Figure 15A). Second, p53, p21, Bax and Noxa RNA levels relative to VHL were compared in 
normal tissues and in VHL wild-type ccRCC. Gene expression levels of p53, p21, Bax and Noxa 
in tumor tissue with wild-type VHL were similar to the ones seen in normal tissues (Figure 15B). 
 
Figure 15: A: VHL RNA levels in normal tissue, and in wild type and mutant VHL ccRCC; B: 
RNA levels of p53, p21, Bax, Noxa relative to VHL transcription levels in normal kidney tissues 
(3 samples).  
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Finally, we equalized all VHL RNA levels across the samples to present the relative transcription 
levels of p53, p21, Bax and Noxa compared to VHL. The RNA levels of p53 and its downstream 
targets relative to VHL transcription levels were assessed in ccRCC samples expressing the 
mutant forms of VHL (Figure 16).  
Relative RNA in tumor tissue
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Figure 16: RNA levels of p53, p21, Bax, Noxa relative to VHL transcription levels in each tumor. 
No tissue with VHL mutation Ser65Trp and Tyr98His was available in our cohort. For each target 
the RNA level of the VHL wild-type tumor is used as reference and compared to the RNA levels 
of the other tumors. In red, pVHL deficient; in blue, pVHL wild-type; in green, pVHL mutated in 
p53 binding domain; in purple, pVHL mutated in HIF binding domain. P-value: *<0.05, **<0.01, 
***<0.001 
Similarly to the established cell lines, wild-type VHL tumor showed generally higher relative 
RNA levels of p53 and its downstream targets than VHL mutated tumors. All except the 
Cys162Arg mutant displayed significantly lower levels of p53 RNA. All 8 mutant samples 
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showed a significant decrease of p21 RNA levels compared to VHL wild-type. In contrast to VHL 
wild-type tumor, significant Bax transcription downregulation was seen in all samples except for 
Cys162Arg and Arg161Pro. All mutants except for Cys162Arg showed lower Noxa transcription 
levels compared to wild-type. We saw that tissues with VHL missense mutations located in p53 
binding domain were not more affected in p53 signaling than tissues with mutations in HIF 
binding domain. Additionally, the mutation Arg161Pro which highly destabilize pVHL did not 
lead to a bigger decrease in p53 and its downstream targets relative RNA levels than mutations 
not affecting pVHL stability. 
e. Effects of HIF and p53 binding site-specific VHL mutations on cell 
proliferation and apoptosis 
The apoptotic behavior of cells expressing different VHL missense mutations was evaluated by 
Caspase 3/7 assay. All pVHL mutants were deficient in apoptosis compared to VHL wild type 
(Figure 17A). By grouping the missense mutations located in the p53 and HIF binding domains, 
respectively, the HIF binding site-specific VHL mutations showed significantly higher apoptotic 
activity than the cell lines with mutations that affected the p53 binding domain (p-value=0.0088) 
(Figure 17B). Cell proliferation was not significantly influenced by the different VHL mutants, 
neither by expression of missense mutations located in the p53 nor in the HIF binding domain 
(Figure 17C-D). 
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Figure 17:   VHL mutations and apoptotic behavior of A: all stable cell lines and B: cell lines 
grouped according to missense mutations in the p53 binding domain and in the HIF binding 
domain; VHL mutations and proliferative behavior of C: all stable cell lines and D: cell lines 
grouped according to missense mutations in the p53 binding domain and in the HIF binding 
domain. In red, pVHL deficient; in blue, pVHL wild-type; in green, pVHL mutated in p53 
binding domain; in purple, pVHL mutated in HIF binding domain. VHL30 expression was used 
as reference and compared to the other cell lines. P-value: *<0.05, **<0.01 
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f. Proliferative and apoptotic behavior of cells upon treatment with 
camptothecin and/or sunitinib 
Camptothecin, which stabilizes and activates p53, was applied to the stable cell lines alone or in 
combination with Sunitinib. Whereas Sunitinib affects the proliferation pathway, Camptothecin is 
known to affect both apoptosis and proliferation [92-94]. BrdU and caspase assays were 
performed with the treated cells and normalized to the number of cells to evaluate the different 
response to the treatment depending on the VHL mutation expressed. 
As expected, treatment with Camptothecin alone or in combination with Sunitinib highly 
increased apoptosis in all cell lines, whereas Sunitinib alone had no effect on apoptosis. Cells 
with Arg161Gln, Arg161Pro and Tyr98Asn showed the highest response to Camptothecin alone 
and Arg161Gln and Tyr98Asn seemed to benefit even more from the combined treatment (Figure 
18A).  All three treatment strategies induced a decrease in cell proliferation except for Arg161X 
for which the treatment with Sunitinib alone showed only a small decrease in proliferation 
(Figure 18B). The response to the different treatments seems to be independent of the mutations 
type, and was similar for cell lines with missense mutation in the p53 binding domain and in the 
HIF binding domain. 
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Figure 18: VHL mutations and apoptotic and proliferative behavior of the different stable cell 
lines after treatment with Camptothecin, Sunitinib, alone or in combination A: on apoptotic 
behavior, B: on proliferative behavior. The signal after treatment of each cell line (treated) is 
normalized to its own mock signal (untreated). VHL30 is used as reference and is compared to 
the other cell lines. P-value: *<0.05, **<0.01 
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The summary of each cell line predicted and observed behavior towards HIF degradation and p53 
signaling is shown in Table 9. 
Table 9: Comparison of predicted effects of the VHL mutations in our stable cell lines and 
experimental results for HIF degradation and p53 pathways 
 
C. Discussion 
In breast, ovarian, bladder and colorectal cancer, p53 accumulation is often due to mutations 
[125-128], whereas in ccRCC p53 is rarely mutated [79, 80]. By investigating p53 expression in 
262 ccRCC cases on our TMA, we saw a relationship between p53 expression and the type of 
VHL mutation:  p53 expression decreases with the severity of VHL mutation. Among the cases 
that were p53 negative, 53% had VHL LOF mutations, 21% had missense mutations, and 26% 
were wild-type. For the cases with high p53 expression, 25% were LOF, 29% missense, and 46% 
wild-type. 
Our immunohistochemistry was consistent with other studies showing that p53 expression was 
significantly lower in ccRCC than in other RCC subtypes [75, 76, 129, 130]. Our result of the 
correlation between severe VHL mutations and negative or low p53 expression suggests that, in 
contrast to other tumor types, p53’s absence may be a consequence of severe VHL mutations 
leading to the incapability of pVHL to bind and stabilize p53 in ccRCC.  
As different mutation types in a gene may exert different effects on the function(s) of its protein, 
we attempted to investigate missense mutations that may specifically affect p53 and its 
Babe (Ser65Trp)
VHL30
Leu158Val
Arg161Gln
Cys162Arg
Arg161Pro
Tyr98His
Tyr98Asn
Arg161X
*known from literature
strongly altered --> strongly altered
strongly altered --> strongly altered
functional --> slightly altered
slightly altered --> altered
strongly altered --> slightly altered
functional --> strongly altered
strongly altered --> strongly altered
slightly altered --> slightly altered
altered --> altered
strongly altered --> strongly altered
Cell lines stably expressing HIF degradation pathway p53 pathway
functional --> slightly altered
prediction  --> Western Blot  
strongly altered* --> strongly altered
functional --> functional
functional --> functional
prediction  --> Caspase & qPCR assay
functional --> strongly altered
functional --> functional
strongly altered --> strongly altered
strongly altered --> strongly altered
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downstream signaling. Therefore, we selected 4 missense mutations identified in the p53 binding 
domain, and 2 missense mutations in the HIF binding domain. The missense mutations were 
predicted to have a range of effects on protein stability, from highly destabilizing to neutral , thus 
leading to different regulation of the HIF degradation pathway as previously described [43]. As 
the p53 binding domain is overlapping with the ElonginC binding domain [64], the missense 
mutations in this region may potentially affect pVHL interactions with one or with both binding 
partners. We first wanted to verify the HIF degradation pathway of these mutants. 
The VHL mutations Cys162Arg, Arg161Pro and Arg161X were unable to downregulate HIF1/2α 
at the protein level. This result was expected for Arg161Pro due to its predicted effect on stability 
and for the nonsense mutation Arg161X. Interestingly, Cys162Arg which is located in the 
p53/ElonginC domain and predicted to be neutral was unable to downregulate HIF1/2α. It is 
therefore possible that mutant Cys162Arg impairs ElonginC binding, thus leading to HIF 
accumulation. Mutants Arg161 Gln (occurring in p53/EloC binding site), and Tyr98His and 
Tyr98Asn (HIF binding site) remained only partly functional for HIF degradation which is 
consistent with the stability prediction and the mutation location. Finally, like VHL30, 
Leu158Val was able to fully downregulate HIF1/2α. Notably, Arg161Gln and Tyr98His had a 
milder effect on HIF1α degradation than on HIF2α. Although p53 was demonstrated to be 
stabilized by wild-type pVHL [64], p53 expression seemed to be unaffected by the VHL 
mutations in our stable cell lines. Only Leu158Val showed an elevated signal for HIF reporter 
activity while it was efficiently downregulating HIF1/2α at the protein level. In summary, 2 of 
the missense mutations located in p53/EloC binding domain were still able to downregulate HIF. 
Since p53 expression appeared unaffected by VHL mutations, we hypothesized that those 
mutations could affect p53 activity rather than stability in our stable cell lines. The detection of 
phosphorylated forms of p53, representing its activation status, was difficult to assess by Western 
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Blot. In a previous study it was shown that pVHL wild-type enhances p53 transcriptional activity 
for its downstream targets p21 and Bax. In addition, pVHL missense mutant Tyr98Asn caused 
loss of the ability to bind HIF1α, but had no negative effects on p53 binding [64]. Therefore we 
analyzed p53 and its downstream targets p21, Bax and Noxa for their transcription levels to have 
on overview of p53 signaling upon VHL mutations in our cell lines. 
The RNA levels in the stably transfected cell lines were investigated for p53 and its downstream 
targets. Indeed, the RNA level of p53, p21 and Noxa were lower in all VHL mutant cell lines 
compared to those in RCC4 VHL30. Bax RNA levels were hardly affected by the VHL mutations. 
We also analyzed the RNA levels of p53 and its downstream targets in ccRCC tissue which had 
the same mutations selected for our stable cell lines with 2 exceptions.  None of our tumor tissues 
had Ser65Trp (to mimic endogenous VHL mutation of RCC4) or Tyr98His. VHL was transcribed 
at similar levels in tumor and in normal tissue. p53 signaling was comparable in VHL wild-type 
ccRCC and in normal tissue. In VHL mutated tumors RNA levels of p53, p21, Bax and Noxa 
were much lower than in tumors with VHL wild-type which was also observed in the cell lines. 
To investigate the effect of the impaired p53 signaling caused by VHL mutations, we investigated 
the apoptotic and proliferative behavior of our stable cell lines. 
All our selected VHL mutations led to an attenuated apoptosis compared to VHL wild-type, but 
no significant change in cell proliferation was seen. Given their apoptosis deficiency, VHL 
mutants have a survival advantage compared to VHL wild-type. In a previous study, the VHL 
mutants S111R and S111C (part of the HIF binding domain) showed a decrease in apoptosis 
compared to wild-type via impairment of recruitment of coactivators p300 and Tip60, although 
p53 binding remained unaffected [65]. The loss of ability to recruit coactivators of p53 could 
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explain the low apoptotic activity of our cell lines with missense mutations outside the p53 
binding domain. 
By combining the cell lines in two groups according to their mutation locations, cells with a 
missense mutation in the p53 binding domain were less apoptotic than cells with missense 
mutations affecting the HIF binding domain. Hence, cell lines with missense mutations in the p53 
binding site had a better survival than the ones that were mutated in the HIF binding domain.  
Since all pVHL mutants showed attenuated apoptosis compared to wild-type pVHL, we treated 
the cells with Camptothecin, a chemotherapeutic drug that stabilizes and activates p53 by 
inducing DNA damage and decreases cell proliferation. Sunitinib, which is the current treatment 
of choice for ccRCC, is a TKI targeting VEGFR2 and PDGFRβ and also negatively influences 
cell proliferation. Camptothecin considerably increased apoptosis in all cell lines including VHL 
wild-type, whereas Sunitinib had no apoptotic effect. For cell proliferation, all three treatment 
modalities (Camptothecin alone, Sunitinib alone or both combined) showed an average of 50% 
decrease in proliferation. With exception of Arg161X mutant cells which had a lower response 
(20% decrease in proliferation), all cell lines responded well to Sunitinib alone. Interestingly, 
cells with VHL mutations in the p53 binding domain or with a mutation in HIF binding domain 
showed the same response to the three treatments. 
In summary, Camptothecin was more effective than Sunitinib because not only it decreased 
proliferation but also increased apoptosis for all the different VHL mutated cell lines. Finally, the 
response to treatment did not seem to depend on the missense mutation location and the binding 
domain affected. VHL mutation status cannot explain (at least alone), the low response response 
rates observed with TKI treatments in patients. 
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D. Conclusion 
In this study, we showed that p53 expression is inversely correlated to VHL mutations severity. 
We attempted to characterize the effects of missense mutations specifically located in the p53 
binding domain of pVHL in terms of HIF degradation, p53 signaling, and their impact on cells 
behavior and response to treatment. Among the missense mutations selected, we found that 2 out 
of the 4 mutations occurring in p53 binding domain were still able, at least partially, to 
downregulate HIF1/2α and therefore their downstream targets CAIX and Glut1, meaning those 
mutations were still able to bind both HIF and ElonginC. The 2 other missense mutations in this 
binding site could not downregulate HIF, most probably because of their effect on protein 
stability (Arg161Pro) and loss of binding to ElonginC (Cys162Arg) since the p53 and ElonginC 
interaction sites are overlapping. We showed that all VHL mutations led to lower RNA levels of 
p53 and its downstream targets p21, Bax and Noxa compared to VHL wild-type both in our stable 
cell lines models and in tumors. We next investigated the effects of these mutations on cells 
behavior and found that all VHL mutations showed attenuated apoptosis but had no effect on 
proliferation. When we focused on the missense mutation location we saw that mutations 
affecting p53 binding domain were even more deficient in apoptosis than mutations in HIF 
binding domain, thus providing a growth advantage to cells with VHL missense mutations in p53 
binding site. We treated cells with Camptothecin or Sunitinib and found that Camptothecin but 
not Sunitinib was capable of increasing apoptosis, and that both treatment strategies could 
efficiently diminish proliferation. We saw no benefit in combining both drugs compared to 
Camptothecin alone in our stable cell lines. The different VHL mutations did not seem to have on 
impact on the treatment response to the different treatment strategies. Finally, Camptothecin was 
proven more efficient than Sunitinib to lower cell growth, as it is targeting both apoptotic and 
proliferative pathways. Camptothecin has been investigated in preclinical and initial clinical trials 
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for ovarian and breast cancer, and is now studied in the context of ccRCC [44-46]. In these 
studies, the effects of Camptothecin on proliferation and apoptosis have been studied and the 
drug has been proven more efficient in the presence of pVHL and, contrary to what has been seen 
in our stable cell lines, it is thought to improve the efficacy of anti-angiogenic drugs. In 
conclusion, we saw that specific missense mutations of VHL lead to specific pathways 
deregulation, and that the use of a p53-mediated chemotherapy could be useful for ccRCC, 
independent of VHL mutations. The mechanism of chemotherapy resistance in ccRCC does not 
seem to depend on VHL mutations either and need further investigations. 
E. Addendum 
We attempted to investigate the interaction between pVHL and p53 by different experiments that 
were inconclusive. In this part are presented the results of these trials. 
a. p53 reporter assay 
VHL30 showed a higher p53 activity than Arg161Gln, Cys162Arg and Tyr98Asn but a lower 
activity than the other mutations. None of the mutant pVHLs showed a significant difference 
compared to pVHL wild-type (Figure 19). The several repeats of this experiments showed that 
the results were highly variable and hardly reproducible (the mean of 3 repetitions is shown 
here). To determine the p53 activity induced directly by pVHL, Babe and VHL30 were treated 
with a VHL siRNA and compared to the untreated cells (3 repetitions). Although we see a 
significant decrease in p53 activity upon VHL downregulation (50% decrease for Babe and 60% 
for VHL30), the global level of p53 activity is higher in Babe than in VHL30, which is not 
consistent with what is seen in the quantitative PCR experiment, where mutant pVHL showed 
lower RNA levels of p53 targets than wild-type pVHL.  
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Figure 19: p53 signaling in the established cell lines and in RCC4 Babe and VHL30 upon VHL 
knockdown. P-value: *<0.05 
b. pVHL pull-down and co-immunoprecipitation of ElonginC and p53 
pVHL is expressed in lysates Leu158Val, Arg161Gln, Cys162Arg, Arg161Pro, Tyr98His, 
Tyr98Asn and Arg161X in input as well as in IP lanes. Elongin C co-immunoprecipitated with 
pVHL in lysates Leu158Val, Arg161Gln, Tyr98His, Tyr98Asn and Arg161Gln but not in 
Cys162Arg and Arg161Pro which is consistent with the level of HIF seen in Western Blot. p53 
co-immunoprecipitated in lysates Babe, Leu158Val, Arg161Gln, Cys162Arg, Arg161Pro, 
Tyr98Asn and Arg161X (Figure 20). Unfortunately, the VHL30 lysate that is supposed to be the 
positive control of this experiment had lost VHL plasmid expression and cannot be used as 
reference since pVHL is not seen even in VHL30 input, as it has been verified by PCR 
amplification of the vector (Figure 21).  
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Figure 20: Different pVHL forms binding ability to p53 and EloC 
 
 
 
 
 
 
Figure 21: Gel electrophoresis of PCR amplification of stable cell lines DNA using a forward 
primer in the vector backbone and a reverse primer in VHL. 
This experiment has been carried out several times with different amounts of total protein for co-
immunoprecipitation and with a proper VHL30 lysate but this result could not be exactly 
reproduced.  
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c. Surface Plasmon Resonance (SPR) 
Preliminary results of the assay showed a binding of 32 Refraction Units (Figure 22) but this 
result could not be reproduced after several trials and no binding was seen between pVHL and 
HIF1α. Several artefacts might indicate that the proteins were too fast degraded and that they 
were not adequately folded.  
 
 
 
 
 
 
Figure 22: SPR measurement of p53 binding to pVHL. In green: Startup assays, running buffer is 
injected. In red: 100nM p53 in running buffer is injected. pVHL has been immobilized on the 
surface (200 RU). P53 binds pVHL WT (32 RU) 
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d. Mammalian two-hybrid assay 
 Although the positive control for the assay (mouse-p53 + SV40 T antigen) showed a high 
increase of the signal, the co-transfection of pVHL and ElonginC or p53 showed no increase in 
the luciferase activity (Figure 23). Cloning ElonginC and p53 in pCF2 and VHL in pCF1 and co-
transfecting ElonginB to stabilize pVHL could not solve this issue. 
Figure 23: Luminescence signal from mammalian double-hybrid assay for pVHL-p53/EloC 
interaction 
65 
 
V. Comprehensive investigation of the mutational landscape in 
clear cell Renal Cell Carcinoma and its correlation to treatment 
response  
Despite the obvious importance of VHL alteration in ccRCC development, this gene alone cannot 
entirely explain tumorigenesis. Several other genes, notably involved in chromatin remodeling, 
were recently found to be frequently mutated in ccRCC as well. Since VHL mutations alone do 
not clearly correlate with treatment outcome, we used NGS on a cohort of 30 patients treated with 
anti-angiogenic drugs to search for a possible relation between other genes alterations and 
therapy response. 
A. Abstract 
Introduction: Sporadic renal cell carcinoma (RCC) is divided into different subtypes from which 
clear cell Renal Cell Carcinoma (ccRCC) is the most frequent and aggressive form. Formation of 
ccRCC is thought to be closely connected to the functional loss of the von Hippel-Lindau (VHL) 
tumor suppressor gene which is mutated in up to 70% of the cases. Data of recent studies indicate 
that the loss of pVHL function may be not sufficient to cause ccRCC. In addition, several other 
genes, such as PBRM1, SETD2 and BAP1, have recently been found mutated in ccRCC as well. 
We hypothesized that mutational patterns specific for the clear cell tumor subtype exist, which 
may have impact on the patients’ response to therapy. 
Methods: In this study, we used the IonTorrent technology using the Ion Proton instrument and 
the Ion AmpliSeq™ Comprehensive Cancer Panel. The experiment was conducted on 30 ccRCC 
samples and focused first on 18 RCC-related genes including VHL, SETD2, PBRM1, MTOR, 
PDGFRA, TSC1, PIK3CA, BAP1, CARD11, PDGFRB, KDM5C, KDM6A, EGFR, TP53, HIF1A, 
NF-κB, PTEN, and PDGFB. The ccRCC patients were treated with Tyrosine Kinase Inhibitors, 
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mTOR inhibitors or immunotherapy after surgery. 18 patients presented with progressive disease, 
nine had stable disease and six had regressive disease. Sequencing data were analyzed using the 
Ion Reporter variant caller, CLC genomics workbench and the Integrative Genomics Viewer 
visualization tool. Total variants found were filtered based on two criteria, a coverage higher than 
30 reads and an allele ratio higher than 5%. 
Results: All tumors showed at least one variant in one of the selected genes. The genes with the 
highest mutation rates were VHL (83%: 25/30), PBRM1 and SETD2 (60%: 18/30), MTOR (50%: 
15/30) and PDGFRA (37%: 11/30). We are currently investigating the impact of the variants on 
the treatment response and extend the sequence analysis in more detail to all 400 genes with the 
support of bioinformaticians. 
Conclusion: Deciphering individual gene mutation maps may give rise to the pathways being 
altered in ccRCC, thus revealing new therapeutic options. 
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B. Results 
a. Patients 
Sanger sequencing of 30 patietns revealed 5 wild-type and 25 with VHL mutations (83%). In-
frame, frameshift deletions and insertions were found in 13 patients (43%), nonsense mutations in 
4 patients (13%), splice site mutations in 2 patients (7%) and missense mutations in 7 patients 
(23%). One patient had two mutations, one nonsense and one missense. The details of the clinical 
data, VHL mutation status determined by Sanger sequencing, treatments and responses are shown 
in Table 10. An overview of the patients’ survival, stage and grade of the tumor is presented in 
Figure 24. 
Table 10: Treatment, response, and VHL mutation status of the patients treated with anti-
angiogenic therapies. 
 
 
Patient's ID VHL  mutation Mutation consequence Disease progression status Treatment pT stage Fuhrman grade
75 c.163delG/p.Glu55ArgfsX11 frameshift PD Votrient>Afinitor 3 3
42 c172delC/p.Arg58GlyfsX9 frameshift PD IFNa>Votrient
16 c.194C>T/p.Ser65Leu missense PD Sutent
19 c.240T>A/p.Ser80Arg missense PD IFNa>Sorafenib 1
40 c. 262T>A/p.Trp88Arg missense PD Sutent 3 3
14 c.268_273del/p.Asn90_Phe91del in frame PD Sutent 3
6 c.IVS1+1G>A (c.340+1G>A) splice mut PD Nexavar>Sutent>Afinitor
5 c.345_364del/p.Leu116ArgfsX9 frameshift PD IFNa>Nexavar
13 c.349delT/p.Trp117GlyfsX42 frameshift PD Sutent 3 3
8 c.484T>C/p.Cys162Arg missense PD Sutent>Nexavar>Afinitor>Votrient 3 3
71 c.497_505del9/p.Arg167ValdelSerLeu in frame PD Sutent 3 3
15 C.580_583delinsAA/p.Val194LysfsX61 frameshift PD Sutent>Nexavar
3 c.586A>T/p.Lys196X nonsense PD Sutent>Nexavar>Afinitor>Everolimus 1
34 wild-type PD Votrient 3 4
61 wild-type PD Sutent>Votrient>Nexavar>Afinitor 4 3
69 wild-type PD Sutent 2 3
17 c.161_162delTG/p.Met54ArgfsX77 frameshift SD Sutent 3 4
74 c.203C>A/p.Ser68X nonsense SD Nexavar/Gemzar/Xeloda>Votrient> Everolimus 3 4
7 c.327insA/p.His110ProfsX22 frameshift SD Sutent>Nexavar 1 4
70 c.IVS1+2T>A (c.340+2T>A) splice mut SD Votrient>Axitinib 3 3
48 c.345insC/p.Leu116ProfsX15 frameshift SD Avastin>IFNa>Votrient 3 4
35 c. 350delG/p.Trp117CysfsX42 frameshift SD IFNa/Avastin 1 3
1 c.481C>T/p.Arg161X nonsense SD Nexavar 2 2
12 wild-type SD Sutent>Nexavar>Afinitor
4 c.167_168delCC/p.Ala56GlyfsX75 frameshift RD Nexavar 3 1
72 c.227_229del3/p.Phe76del in frame RD Votrient>Sutent 1 3
39 c.340G>T/p.Gly114Cys missense RD IFNa>Bevacizumab 2 3
76 c.383T>C/p.Leu128Pro * missense RD Votrient 3 4
76 c.430G>T/p.Gly144X * nonsense RD Votrient 3 4
11 c.458T>C/p.Leu153Pro missense RD Sutent 2 3
73 wild-type RD Votrient>Afinitor 3 3
PD: progressive disease; SD: Stable disease; RD: Regressive disease
* one patient with two mutations
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Figure 24: Clinical data overview of the cohort. Survival is unknown for 1 patient; tumor 
stage/grade is unknown for 7 patients. 
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b. Libraries 
Between 11 and 2384 pM of library DNA was obtained. As an example, the Bioanalyzer results 
showing the concentration of 4 libraries evaluated by real-time quantitative PCR and the Sanger 
sequencing result for patient ID #6 are shown in Figure 25. 
A 
 
 
 
B 
 
 
 
 
 
 
 
 
Figure 25: Patient ID #6 example, A: Sanger sequencing mutation analysis, B: Bioanalyzer and 
qPCR results of the 4 libraries  
Library a: 
695pM 
Library d: 
746pM 
Library c: 
650pM 
Library b: 
709pM 
VHL Sanger sequencing: 
c.IVS1+1G>A/c.340+1G>A 
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c. Runs summary 
The sequencing of the 30 patients was performed in two runs of 15 patients each. 
The two runs produced about 80 million reads, more than 85% of the wells were loaded and in 
total more than 60% of the reads were usable for analysis. The average “on target” reads was 
98% and the average depth was 275 for both runs. The mean reading length of the amplicons was 
about 110bp. The summary of the runs is shown in Figure 26. 
1st run: patients ID #1-19 
 
 
 
 
 
 
 
2nd run: patients ID #34-76 
 
 
 
 
 
Figure 26: Runs summary 
8,4 Gbases; 78,968,409 reads 
9,3 Gbases; 85,070,870 reads 66% usable reads 
62% usable reads 
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d. Variants in the selected genes 
We first focused on a set of 18 genes known to play a critical role in ccRCC and classified 
regarding their major functions (Table 11). VHL, PBRM1, SETD2, BAP1, TSC1, PTEN and TP53 
are additionally qualified as tumor suppressor genes.  
Table 11: Genes selection function/pathway 
Genes Function/pathway 
VHL and BAP1  ubiquitination processes  
PBRM1, SETD2, KDM5C, and KDM6A  chromatin remodeling  
TSC1, MTOR, EGFR, PTEN and PIK3CA  cell growth  
TP53, CARD11 and NF-κB   apoptosis 
HIF1a, PDGFRA and PDGF(R)B   angiogenesis  
 
Fifteen of 25 (60%) VHL mutations that were identified by Sanger sequencing were also called 
by Ion Reporter with our filter criteria. After visual inspection of the reads using IGV, additional 
6 VHL variants were confirmed. Those 6 variants were verified with variant caller CLC 
Workbench. The mutation sites of the 4 remaining “wild type” samples were not or too low 
covered by deep sequencing because no or only few reads were available at those positions. In 
total 21 of 25 (84%) of the VHL mutations detected by Sanger sequencing were confirmed by 
NGS. Patient ID #12 showed a VHL missense mutation (c.162G>A/p.Met54Ile) by NGS that was 
not found by Sanger sequencing. For the analysis, the four VHL mutations revealed by Sanger 
sequencing but not by NGS were included and the additional mutation in patient ID #12 detected 
only by NGS was neglected. The data of variant calling by Ion reporter and CLC, visual 
inspection of the reads by IGV and Sanger sequencing is summarized in Table 12.  
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Table 12:  Summary of variant calling by Ion reporter and CLC, visual inspection of the reads by 
IGV and Sanger sequencing 
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The total number of variants obtained from the 30 patients with our filter criteria was 412 among 
all genes. The number of variants per patient ranged from 171 (patient ID 1#) to 2 (patients ID 
#12, 16, 40, 61). The number of variants per patient is shown in Figure 27A. The genes with the 
highest mutation rates were VHL (83%: 25/30), PBRM1 and SETD2 (60%: 18/30), MTOR (50%: 
15/30) and PDGFRA (37%: 11/30) (Figure 27B).  
A 
 
B 
 
Figure 27:  A: Total number of variants per patient in the 409 genes. B: Mutation rate in our 
selection of 18 genes. 
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Notably, all patients had a mutation in at least one of the selected genes. Patient ID #6 as an 
example had a mutation in VHL and in SETD2, PBRM1 and KDM5C. A heat map showing the 
strongest impact variants of the 18 selected genes in each patient is shown in Figure 28. A patient 
with multiple mutations in the same gene will show only the mutation with the worse effect in the 
heat map. Tumor suppressor genes were mostly affected in 54% of patients showing variants in 
VHL, BAP1, PTEN, PBRM1, SETD2, TSC1 and TP53. The mutation types were mainly missense 
mutations (101, 67.8%) followed by insertion-deletions (23, 15.1%), and nonsense or stop-loss 
(28, 18.4%) mutations. Notably, 95% (20/21) of the insertion-deletions-splice mutations occurred 
in the tumor suppressor genes VHL, PBRM1, SETD2 and BAP1. The other genes were mostly 
affected by missense mutations.  
 
Figure 28: Heat map of the filtered in variants in the 18 selected genes. 
 
Progressive disease Stable disease Regressive disease
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The genes involved in chromatin remodeling were mutated in 31.6% of the patients, followed by 
cell growth regulating genes (22.3%), ubiquitination processes (21.7%), angiogenesis (15.8%) 
and apoptosis (8.6%). The frequencies of mutations in the genes grouped by the function/pathway 
are shown in Figure 29. 
 
Figure 29: Proportion of variants in the 18 selected genes by their related function or pathway. 
e. Mutation spectrum and treatment response 
Patients have been classified in two groups, non-responders (progressive disease) and responders 
(including stable and regressive disease). The proportion of mutant for the combined 18 genes is 
significantly different in these two groups (p-value=0.0217). Patients with regressive disease had 
significantly more mutations than patients with progressive disease (Figure 30A). The mutation 
frequency of each of the selected genes in those two groups is illustrated in Figure 30B. 
Interestingly, PBRM1, BAP1, CARD11 and HIF1α were more mutated in the responder group 
than in patients with progressive disease (79%, 43%, 36%, and 21% of the responder cases versus 
44%, 13%, 13%, and 6.3% in the non-responder group). Additionally, PIK3CA was found 
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mutated in 3 stable or regressive tumors but in none of the progressive disease. The proportion of 
variants in each response group by pathway affected did not show any significant difference 
between the two groups (Figure 30C). 
A                                                                        C 
 
 
 
B 
 
 
 
 
 
 
Figure 30: A: Proportion of wild-type and mutations for our selection of genes in the two groups 
of treatment response. B: Mutation rate for each gene in the two patient outcomes groups. C: 
Proportion of variants in each response group by pathway affected 
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C. Discussion 
In this study, we investigated more than 400 cancer-related genes using NGS and associated 
identified gene alterations and variant clusters with targeted treatment outcomes. We found that 
VHL, PBRM1 and SETD2 were the most often mutated genes in our mccRCC cohort, and that 
they also present the vast majority of insertions, deletions and nonsense mutations, thus being the 
most severely affected genes. We also found that patients responding to anti-angiogenic therapies 
presented significantly more variants than non-responders, especially in the genes PBRM1, 
BAP1, CARD11 and HIF1α. 
In total for VHL sequencing, we found one false positive (3%), two false negative (7%),two 
variants were not covered (7%) and 6 variants that were not called by Ion reporter but that were 
called by CLC (20%). This can be explained by the fact that these two variant callers have their 
own algorithms and some variants can then be eliminated by one but not by the other along the 
pipeline, thus not be reported. Altogether, 83% of the Sanger sequencing results matched the 
NGS results. The systematic use of two different variant callers and the loading of fewer samples 
per run to increase coverage could improve the global performance of variant calling. Patient #12 
presented a VHL mutation in NGS which was not found by Sanger sequencing. This could be 
explained by the low allele ratio (7%) reported by Ion reporter variant caller and the low 
coverage in our Sanger sequencing mutation analysis. Additionally, the location of this missense 
mutation close to the annealing site of the Sanger sequencing primer may interfere with the 
resulting sequence. As Sanger sequencing is still considered as the gold standard for diagnostic 
mutation analysis, the wild-type sequence has been retained and this mutation has been 
considered as a false positive. 
Each patient presented with at least one variant in one of the 18 selected genes, ranging from 2 to 
18 per patient, but the number of mutations alone could not discriminate between the two 
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response response groups. The highest rates of mutations and the most severe impacts (insertions, 
nonsense) were observed in VHL (83%), PBRM1 and SETD2 (each 60%). These results confirm 
recently published results and support the “river model” (Wei et al. [108]) that describe ccRCC 
development with VHL being the first gene altered in ccRCC initiation, followed by secondary 
and tertiary events affecting PBRM1 or SETD2. Following their guideline, would then appear a 
“window of opportunity” for treatment where the hallmarks of cancer are already present and 
after which additional mutations in others genes could be responsible for resistance. MTOR and 
PDGFRA were in the top 5 mutated genes with 50% and 37% respectively. Those genes have 
already been described as highly mutated in ccRCC although the rates were found higher than in 
previous studies [97-102, 105, 106]. This discrepancy can be explained by the use of NGS that 
allows detection of variants between 5% and 15% allele ratio, which is the average detection 
limit of Sanger sequencing. The total number of variants called by Ion Reporter in our selection 
of 18 genes was 384 with an allele ratio >5% and 70 with a >15% allele ratio. BAP1 reached a 
25% mutation rate, which is higher than the reported frequency of 15% [97, 103, 104]. 
Interestingly, the occurrences of variants were very similar to what has been recently reported by 
Ho et al. in a deep-sequencing study in which also TKI-treated mccRCC were analyzed (i.e. 
VHL: 71% vs 83% in our data set, PBRM1: 48.4% vs 60%, TSC1: 29% vs 27%, KDM5C: 16.1% 
vs 20%) [131]. More than 85% of the ccRCC cases were mutated in at least one those genes and 
only 4 patients were wild-type for PBRM1, SETD2, MTOR and PDGFRA, which may represent 
attractive candidates for targeted treatments. The insertions, deletions and nonsense mutations are 
mostly found in the tumor suppressor genes VHL, PBRM1, SETD2 and BAP1 (95% (20/21)), 
which could reflect their importance in ccRCC development. Particularly, PBRM1 and BAP1 
presented a high rate of mutations with severe consequences (50% and 25% of 
insertions/deletions/splice mutations respectively) which confirmed previous observations where 
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high frequencies of truncating mutations were reported in those genes [100, 103]. Current 
therapies repressing VEGF, PDGF and MTOR exist, but treatments tailored to enhance or rescue 
the tumor suppressor functions of VHL, PBRM1, SETD2 and BAP1 remain challenging to design. 
A possible therapeutic strategy could be to target directly effector proteins when their genes are 
altered, and to target the proteins which are in the downstream signaling of affected tumor 
suppressor genes. 
More than half of the mutations affected the tumor suppressor genes  VHL, PBRM1, SETD2, 
BAP1, TSC1, PTEN and TP53. Given the potential pleiotropic regulatory effects of tumor 
suppressors, many different oncogenic processes may be touched by those variants. Regarding 
the pathways possibly affected and activated by those gene alterations, chromatin remodeling, 
cell growth and ubiquitination rather than angiogenesis were involved. 
In general responders were significantly more frequently mutated than non-responders as a 
responder shows in average 5,9 mutations and non-responders 4,3 in our selected genes. 
Notably, PBRM1, BAP1, CARD11 and HIF1α were more affected in patients of the responder 
group. This result confirms recent studies suggesting an association between PBRM1 mutations 
and anti-VEGF therapy response, as those alterations were correlating with a longer progression-
free survival [132] or a prolonged duration of treatment [131]. Interestingly, mutations in 
PIK3CA were only present in three responder patients but in none of the non-responders. This 
gene is mutated in 2 to 5% of ccRCC cases [106, 133]. Its alteration is known to be linked to anti-
EGFR therapy resistance in breast cancer, but was not found predictive for bevacizumab effect in 
colorectal cancer [134, 135]. PIK3CA implications in ccRCC growth and angiogenesis could be 
interesting features to study in the context of VEGF-targeted therapies. Indeed, PIK3CA 
expression has been shown to correlate with the expression of VEGF in ovarian cancer, and its 
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inhibition led to the downregulation of HIF1α and VEGF [136]. In this context, mutations in 
PIK3CA could attenuate expression of VEGF in ccRCC cells, thus acting synergistically with the 
anti-angiogenic therapies, leading to a better response. 
D. Conclusion 
In conclusion, we found that VHL, PBRM1, SETD2, MTOR and PDGFRA were the most 
frequently altered genes in our cohort of ccRCC patients. VHL, PBRM1 and SETD2 were as well 
the most severely affected in terms of mutation impact on the protein. The pathways that were the 
most hit by mutations were chromatin remodeling, growth and ubiquitination before angiogenesis 
that came at the fourth rank but yet is the preferential pathway targeted nowadays in clinics. We 
also found that responder patients were presenting in general more variants than non-responders 
and especially for the genes PBRM1, BAP1, CARD11 and HIF1α.  
E. Addendum 
Seventeen RCC cell lines were investigated by NGS using the same filter criteria as for the 
patients. Twelve cell lines are derived from ccRCC, 3 from adenocarcinoma with no other 
specification, and 2 are derived from normal kidney tissue, adult and embryonic (HK-2 and 
Hek293 respectively). In total, 63 variants were found among the 18 genes of interest selected. 
VHL mutations known by Sanger sequencing were found for 7 cell lines, 2 mutations were not 
covered by the NGS, and 2 others were not called by Ion Reporter but found in the reads after 
visual inspection with IGV and correctly called by CLC with a coverage below 30 but mutations 
found in all the reads (allele ratio = 1). The 6 wild-type cell lines were assessed correctly by Ion 
reporter. The top 5 genes mutated in the cell lines were VHL (11/17), SETD2 (7/17), BAP1, 
PBRM1and MTOR (5/17). The mutation rates for each gene are shown in Figure 31 and the 
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corresponding heat map in Figure 32. The two normal kidney cell lines reported only one variant 
each, in SETD2. 
 
 
 
 
 
 
Figure 31: Mutation rates of the selected genes in RCC cell lines 
 
 
 
 
 
 
 
 
Figure 32: Heat map of the selected genes in RCC cell lines 
SL
R 
23
SL
R 
25
78
6-
0
SL
R 
24
ca
ki
 2
K
C
 1
2
RC
C
4
SL
R 
26
76
9-
P 
SL
R 
22
ca
ki
 1
SL
R 
21
A
49
8
A
C
H
N
A
70
4
H
K
 2
H
EK
 2
93
VHL 11
SETD2 7
BAP1 5
PBRM1 5
MTOR 5
KDM5C 4
HIF1a 3
PDGFRB 3
PTEN 3
TP53 3
PIK3CA 3
CARD11 2
NFkB 2
TSC1 2
KDM6A 1
PDGFRA 1
PDGFB 1
EGFR 0
10 10 5 4 3 3 3 3 2 2 1 1 5 4 3 1 1
Normal tissue
Adenocarcinoma
ccRCC
82 
 
VI. Conclusion 
In this study, we could show that VHL missense mutations can specifically affect single binding 
domains of pVHL, in contrast to VHL loss-of-function mutations which highly likely abrogate all 
multifunctional properties. We observed that especially missense mutations located in the p53 
binding domain influence negatively the p53 signaling pathway and attenuate apoptosis. Cell 
behavior after treatment with Camptothecin or Sunitinib indicates that p53 activator drugs alone 
or in combination with current anti-proliferative TKIs may optimize ccRCC treatment. As there 
was no association of VHL mutation type and response to treatment in ccRCC patients, the 
identification and analysis of mutations in additional driver genes, their combinatorial pattern in 
individual ccRCC and their relation to response/non response is of utmost importance. 
 
 
 
 
 
 
 
83 
 
VII. Material and Methods 
A. Patients and tissue specimens 
To a previously described collection of 256 formalin-fixed, paraffin-embedded (FFPE) tissue 
samples of patients with sporadic ccRCC [43], 90 additional cases from the University Hospital 
of Zürich and 14 from the Clinical Division of Oncology and Cancer Centre, Medical University 
of Vienna, Austria, were reviewed by one pathologist (H.M.). The tumors were graded according 
to the classification of the World Health Organization [12]. The median age of the patients was 
64 years. Tumor stage and Fuhrman grade of the tumors were unknown for 14 patients. The 
cohort consisted of 147 (42.8%) pT1, 31 (9%) pT2, 160 (46.5%) pT3 and 8 (2.3%) pT4 ccRCC. 
There were 11 (3.2%) grade I, 105 (30.5%) grade II, 144 (41.9%) grade III and 86 (25%) grade 
IV tumors (Table 4). This study was approved by the cantonal commission of ethics of Zurich 
(KEK-ZH-nos. 2011-72 and 2013-0629). Areas that contained at least 75% tumor cells were 
directly marked on the HE section of each tumor and considered for punching. 
Thirty patients were treated with at least one of the following anti-angiogenic drugs: Sunitinib, 
sorafenib, pazopanib and bevacizumab. Tumor response was evaluated according to the RECIST 
criteria [137] and was classified into three types of response: progressive disease (16 patients), 
stable disease (8) and regressive disease (6 partial or complete remission) (data provided by Dr. 
Axel Mischo, Department of Oncology, University Hospital Zürich).The details of the treatments 
are shown in Table 6. Patients with stable or regressive disease were combined for the analysis in 
the responder group and patients showing progressive disease in the non-responder group. 
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B. DNA extraction and VHL sequencing 
Total DNA was extracted from 3-4 tissue cylinders (diameter 0.6 mm) punched from each FFPE 
block and processed following the Qiagen DNeasy Blood & Tissue Kit (Qiagen, Germany) or the 
Maxwell® 16 FFPE Tissue LEV DNA Purification Kit (Promega corporation,USA). 
The first 162 base pairs of VHL are rarely mutated and were excluded from sequence analysis 
[33]. The primers used for amplification were 5’-agagtccggcccggaggaact-3’ forward, 5’-
gaccgtgctatcgtccctgc-3’ reverse for exon 1, 5’-accggtgtggctctttaaca-3’ forward and 5’-
tcctgtacttaccacaacaacctt-3’ reverse for exon 2, and 5’-gagaccctagtctgtcactgag-3’ forward and 5’-
tcatcagtaccatcaaaagctga-3’ reverse for exon 3. Sequencing was performed as described 
previously [43]. The sequences were aligned and compared to the NCBI sequence AF010238 
using the informatics tool Sequencher (Sequencher® version 5.3 sequence analysis software, 
Gene Codes Corporation, Ann Arbor, MI USA, [138]). All VHL mutations were validated by a 
second independent PCR and sequence analysis. 
C. In silico analysis of VHL missense mutants 
The effect of missense mutation on the stability of pVHL and its potential association to the 
disease were predicted in silico using the program Site Directed Mutator (SDM) [139]. The 
crystal structure of pVHL was isolated from VBC complex 1lm8.pdb crystal structure (Piccolo 
database) and uploaded into the program to calculate the thermodynamic change (ddG) occurring 
after modification of one amino acid according to the main chain conformation, solvent 
accessibility and hydrogen bonding class.  
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The missense mutations were then classified as follows: 
- ddG <-2.0: highly destabilizing and disease-associated 
- -2.0≤ ddG <-1.0: destabilizing 
- -1.0≤ ddG <-0.5: slightly destabilizing 
- -0.5≤ ddG ≤0.5: neutral 
- 0.5< ddG ≤1: slightly stabilizing 
- 1.0 < ddG ≤2: stabilizing 
- ddG >2.0: highly stabilizing and disease-associated 
The mapping of pVHL’s interactors binding domains has been adapted from Leonardi et al. [50]. 
D. Tissue-Micro-Array (TMA) and immunohistochemistry 
A TMA containing 28 normal kidney tissue cores, 93 other subtypes of RCC  and 262 ccRCC 
cores [140] was stained and scored as previously described for nuclear p53 expression in tumor 
cells using the mouse antibody p53 (clone DO-7, dilution 1:150, Dako A/S) [141].  
The scoring was performed as follows:  
- No nuclear positivity: 0 
- 1-5 nuclei positive: +1 
- 6-10 nuclei positive: +2 
- >10 nuclei positive: +3 
E. VHL mutations selection 
VHL mutation selection was based on the use of Site Directed Mutator (SDM, 
http://mordred.bioc.cam.ac.uk/~sdm/links.php) in silico tool to select missense mutations out of 
360 VHL sequences of FFPE samples from patients with ccRCC. We selected 4 mutations that 
were located in the p53/EloC binding domains of pVHL: 3 were predicted to have no or little 
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impact on the protein stability (Leu158Val, Arg161Gln, Cys162Arg), 1 predicted to highly 
destabilize pVHL (Arg161Pro). Controls located in another region of the protein and one 
nonsense mutation have also been selected (Tyr98His, Tyr98Asn, Arg161X).  
F. Establishment of stable cell lines 
A pcDNA3.1 vector encoding VHL wild-type [43] has been used to generate the selected mutants 
with the Quick Change Lightning site-directed mutagenesis kit (Agilent technologies, United 
States). Subsequently, pcDNA3.1 was subcloned into pBabe vectors for transduction in 
mammalian cells.  
pBabe empty vector and vectors containing the VHL wild-type or the mutant VHL sequences 
were transfected into Platinum-A Retroviral Packaging Cell Line (Cell Biolabs, United States) for 
viral pseudo-particles production according to the X-tremeGENE 9 DNA Transfection Reagent 
3:1 protocol (Roche Diagnostics, Switzerland). The viral supernatant was collected and applied to 
RCC4, a pVHL deficient cell line bearing a Ser65Trp missense mutation, for transduction 
following the manufacturer’s recommendations. Polyclonal batches of the transduced RCC4 were 
then selected with constant concentration of 4ug/mL puromycin for 4 weeks and then maintained 
at 2ug/mL for cell culture. RCC4 wild-type was kindly provided by W. Krek, ETH Zürich, 
Switzerland.  
G. Western Blot 
Cultured cells were lysed using RIPA buffer (Sigma-Aldrich, Switzerland) supplemented with 
proteinase and phosphatase inhibitors (Roche Diagnostics, Switzerland) for 15 minutes on ice and 
centrifuged at 6000rpm for 10 minutes at 4°C. Protein concentration has been determined by 
Protein BCA assay (Thermo Scientific, United States) and 25 or 50 µg of proteins were denatured 
by boiling 5 minutes at 95°C with β-mercaptoethanol and subsequently loaded on a Bis-Tris 
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polyacrylamide gel (Life Technologies, United States). After running, the gel was blotted on a 
PVDF membrane (Bio-Rad, United States) and blocked in 5% non-fat milk TBST 1X solution. 
Primary antibodies were applied overnight at 4°C and appropriate secondary antibody for 1h at 
room temperature in 1% milk or 5% BSA TBST 1X solution. The dilutions used for the primary 
antibodies were 1:1000 for pVHL, HIF1α, HIF2α, CA9, Glut1, EloC, 1:500 for Phospho-p53 and 
1:2000 for p53 and actin. Anti-rabbit secondary antibody was diluted 1:1000, anti-mouse 1:2000 
and anti-goat 1:5000. Detailed information of the antibodies is listed in the following table (Table 
13). 
Table 13: Antibodies information 
Antigen Dilution Name Provider 
pVHL 1:1000 S2-647 BD Biosciences 
p53 1:2000 Ab1101 Abcam 
HIF1α 1:1000 NB100-479 Novus Biologicals 
HIF2α 1:1000 PAB12124 Abnova 
CA-IX 1:2000 M75 J. Zavada, Prague, Czech Republic 
Glut1 1:1000 07-14-01 Millipore 
EloC 1:1000 Sc-1559 Santa Cruz 
Actin 1:2000 MAB15-01 Millipore 
Rabbit 1:1000 7074 Cell signaling 
Mouse 1:2000 Ab672 Abcam 
Goat 1:5000 Sc-2020 Santa Cruz 
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H. RNA extraction and quantitative PCR 
RNA was extracted from cultured cells or from two core punches of FFPE samples using 
Maxwell® 16 LEV simplyRNA and RNA FFPE Purification Kit (Promega corporation,USA). 
Equal amounts of RNA were reversely transcribed into cDNA using the High-Capacity cDNA 
Reverse Transcription Kit. RNA levels were determined by quantitative PCR using TaqMan® 
Gene Expression Assay on the ViiA7 Real-Time PCR System instrument (Applied Biosystems, 
United States). The probes used were Hs00184451, Hs00153340, Hs00355782, Hs00180269, 
Hs00736699, Hs00936377 and Hs01026146 for VHL, p53, p21, Bax, Noxa, HIF1α and HIF2α 
respectively and the results were normalized to PPIA housekeeping gene (Hs99999904) RNA 
level in each sample. For the tumor tissue samples, we presented the relative RNA levels of the 
targets compared to VHL transcription levels. The results were displayed as Relative Quantity 
(RQ).  
I. HIF and p53 reporter assays 
The transcriptional activity of HIF and p53 were evaluated using Cignal Reporter luciferase Kit 
(Qiagen, Switzerland) and luciferase activity was measured by Dual-Luciferase® Reporter Assay 
System (Promega Corporation, United States) according to manufacturers’ protocols.  
J. Proliferation and Apoptosis assays 
To investigate the proliferative and apoptotic behavior of the established cell lines we used a 
colorimetric Cell Proliferation ELISA BrdU assay (Roche diagnostics, Switzerland) and a 
Caspase-Glo® 3/7 Assay System (Promega corporation, United States) respectively.  
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K. Cells counting 
To determine the number of cells, MTT assays (Invitrogen, United States) were performed in 
parallel of each proliferation and apoptosis assays. Cell number was calculated by plating RCC4 
Babe cells ranging from 1000 to 8000 cells as a standard curve and MTT signal was correlated to 
the number of cells. This standard curve was used to assess the number of cells in each well in  
all experiments for normalization. 
L. Drugs treatment 
Camptothecin and Sunitinib (Selleck Chemicals, USA) were diluted in DMSO at 0.05uM and 
10uM concentration respectively and applied to the cells alone or in combination at a final 
concentration of 0.3% DMSO for 48h. The vehicle control with 0.3% DMSO was referred to as 
“mock” and “mock VHL30” was used as a reference. 
M. VHL knockdown 
VHL knockdown was performed for the p53 reporter assay using HP Genome Wide siRNA 
Hs_VHL_5 and All stars Negative control siRNA at 2pM final concentration following 
manufacturer’s recommendation (Qiagen, Switzerland). 
N. Co-immunoprecipitation 
In the established stable cell lines, pVHL has been pulled down to verify its ability to co-
immunoprecipitate with ElonginC and p53. Cells were lysed in a non-denaturing lysis buffer 
supplemented with proteinase and phosphatase inhibitors (Complete Mini and PhosSTOP 
Roche). Co-immunoprecipitation (co-IP) was performed using the protein G immunoprecipitation 
kit according to the manufacturer’s recommendations (Sigma-Aldrich, Switzerland). Per cell line, 
7mg of total lysate was used for pVHL pull-down with 2ug of anti-VHL antibody (S2-647, BD 
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Biosciences). For each cell line, 25ug of input and 2 mg of co-immunoprecipitation lysate have 
been loaded side by side on a Bis-tris gel for Western Blot. pVHL, ElonginC and p53 expression 
have been verified as described in the Western Blot section. 
O. Surface Plasmon Resonance 
SPR was used to measure the binding characteristics of pVHL with HIF1α and p53.  
pVHL wild-type, HIF1α wild-type and p53 wild-type have been purchased as >95% pure 
proteins: Human HIF1α Protein (HIF-1α, N-terminal activation domain NTAD 
[AA530-698]), Made in E.coli, with His Tag; Human TP53/P53 Protein, Made in E.coli, with 
GST Tag; Human VHL Protein, Made in Sf21 Insect Cell, with His Tag (SPEED BioSystems, 
LLC, USA). The ligand, pVHL, has been immobilized on the gold layer surface of a CM5 chip at 
pH 4.5 and p53 has been injected through the flow-cell and the change in the refracted light on 
the surface induced by p53 binding to pVHL has been measured on a BIAcore T100 instrument 
(GE Healthcare, USA).  
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P. Mammalian double-hybrid assay 
Elongin C, p53, VHL wild-type and the seven mutants have been cloned into suitable vectors to 
perform mammalian double hybrid assay. The pCF1 (Gateway compatible) vector contains the 
herpes simplex virus VP16 activation domain and the pCF2 vector contains the yeast GAL4 
DNA-binding domain upstream of a multiple cloning region. The pGRE x5E1bluc contains five 
GAL4 binding sites upstream of the firefly luciferase gene. The vectors were kindly provided by 
Prof. Roland Wenger (UZH, Switzerland). ElonginC and p53 have been cloned in the pCF1 
vector and VHL in the pCF2 vector. pCF1, pCF2 and pGRE x5E1bluc were cotransfected in Hela 
cells with a vector constitutively expressing the Renilla reniformis luciferase for normalization. 
The fusion proteins expression has been verified by Western Blot.  
Q. Library preparation and deep sequencing 
All library preparation steps and sequencing material were used following the manufacturer’s 
recommendations (Life Technologies). 
Libraries were generated using Ion AmpliSeq Comprehensive Cancer Panel covering 409 cancer-
related genes. 40ng per sample (10ng per pool) were amplified and the primers were partially 
digested to ensure the production by ligation of barcoded libraries using IonXpress barcoded 
adapters. The barcoded libraries obtained were then purified and 5 additional cycles of 
amplification were performed before a final purification. Libraries quality and quantity were 
assessed using Agilent 2100 Bioanalyzer (Agilent Technologies, USA) and real-time quantitative 
PCR (Ion Library TaqMan Quantitation Kit, ViiA7 Real-Time PCR System instrument (Applied 
Biosystems, United States)). The libraries were combined (15x4 libraries per run) at a 10pM final 
concentration. Templated beads were prepared and enriched using the Ion PI Template OT2 200 
Kit v3 on the Ion OneTouch 2 System and were submitted to quality control using Ion Sphere™ 
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Quality Control Kit. The beads were then loaded on an ion semi-conductor chip using the Ion PI 
Chip Kit v2. The Ion Proton System was used for sequencing and the reads were aligned to hg19 
human reference genome by Torrent Suite.  
R. NGS variant calling and data analysis 
Base calling and variant report were performed with Ion reporter v.4.2 and CLC Genomics 
Workbench v.8.0.64. Sequencing reads could be visually inspected with Integrative Genomics 
Viewer (IGV) [142, 143]. A heatmap of the variants was generated by Ion reporter v.4.2 for a 
selection of 18 genes of interest: VHL, SETD2, PBRM1, MTOR, PDGFRA, TSC1, PIK3CA, 
BAP1, CARD11, PDGFRB, KDM5C, KDM6A, EGFR, TP53, HIF1A, NF-κB, PTEN, and 
PDGFB. The filtering criteria used were coverage over 30 reads, and 0.05 allele ratio count for 
all types of mutations occurring in exonic and splice sites regions of the genes. The small 
nucleotide variations (SNV) listed in the UCSC genome browser site as “common small 
nucleotide polymorphism” (SNP) were filtered out [144]. Variants found in more than 90% of the 
samples (27/30 patients) were considered as false positive and neglected as they were checked in 
our Sanger sequencing internal database. 
S.  Statistics 
Two-tailed Chi square and Student’s t-tests were performed using the program Graphpad prism 
5.04 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com). 
Preferentially mutated codons of VHL were determined by calculating observed and expected 
frequencies of 88 missense mutations.  
A two-tailed N-1 Chi-square statistical test was used to evaluate the difference in proportion of 
mutated cases found by NGS in the two response groups for each of the selected genes. 
P-values are represented as follows: *<0.05, **<0.01, ***<0.001 
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VIII. Annex 
Supplementary table 1: List of all VHL mutations (exon 1)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
256 cases previously described (Rechsteiner et al.)
nt AA codon Mutation Mutation consequence
Exon 1 161 53  c.161insG/ p.Met54IlefsX78 fs
167 56 c.167_168delCC/ p.Ala56GlyfsX75 fs
180 60 c.180_205del/ p. Pro61ArgfsX62 fs
183 61 c.183delC/ p.Val62CysfsX5 fs
183 61 c.183C>G/ p.Pro61Pro silent
183 61 c.183delC/ p.Val62CysfsX5 fs
189 63 c.189_190insCT/ p.Arg64CysfsX4 fs
192 64 c.192_198del/p.Ser65ThrfsX92 fs
193 65 c.193T>A/p.Ser65Thr missense
194 65 c.194C>A/ p.Ser65X nonsense
194 65 c.194C>A/ p.Ser65X nonsense
194 65 c.194C>T/ p.Ser65Leu missense
194 65 c.194C>A/ p.Ser65X nonsense
194 65 c.194C>A/ p.Ser65X nonsense
194 65 c.194C>A/ p.Ser65X nonsense
194 65 c.194C>A/ p.Ser65X nonsense
194 65 c.194C>A/ p.Ser65X nonsense
196 66 c.196_204del/ p.Val66_Ser68 in frame
199 67 c.199insG/ p.Asn67GlufsX65 fs
202 68 c.202T>A/p.Ser68Thr missense
203 68 c.203C>A/ p.Ser68X nonsense
203 68 c.203C>A/ p.Ser68X nonsense
209 70  c.209_226del18/ p.Glu70_Phe73delinsVal in frame
214 72 c.214T>C/p.Ser72Pro missense
214 72 c.214_216delTCC/ p.Ser72del in frame
215 72 c.215_216delCCinsA/ p. Ser72ThyfsX87 fs
217 73 c.217C>T/ p.Gln73X nonsense
221 74 c.221T>A/p.Val74Asp missense
224 75 c.224delT/ p.Ile75ThrfsX84 fs
224 75 c.224delT/ p.Ile75ThrfsX84 fs
225 75 c.225_251del27/ p.Ile75_Val84delinsMet in frame
227 76 c.227delT/ p.Phe76SerfsX83 fs
227 76 c.227_229delTCT/ p.Phe76_Phe76del in frame
227 76 c.227_229delTCT/ p.Phe76_Phe76del in frame
227 76 c.227delT/ p.Phe76SerfsX83 fs
227 76 c.227insG/ p.Phe76CysfsX56 fs
227 76 c.227_229delTCT/ p.Phe76_Phe76del in frame
231 77 c.231C>A/p.Cys77X nonsense
231 77 c.231C>A/p.Cys77X nonsense
232 78 c.232A>T/ p.Asn78Tyr missense
233 78 c.233A>G/ p.Asn78Ser missense
234 78 c.234T>A/p.Asn78Lys missense
234 78 c.234T>A/p.Asn78Lys missense
234 78 c.234T>G/p.Asn78Lys missense
234 78 c.234insA/ p.Asn78LysfsX54 fs
238 80 c.238_239delAG/ p.Pro81AlafsX50 fs
239 80 c.239G>A/ p.Ser80Asn missense
240 80 c.240T>A/ p.Ser80Arg missense
240 80 c.240T>A/ p.Ser80Arg missense
245 82 c.245G>C/ p.Arg82Pro missense
251 84 c.251T>A/p.Val84Glu missense
256 86 c.256C>A/ p.Pro86Thr missense
257 86 c.257C>A/ p.Pro86His missense
261 87 c.261insT/ p. Trp88MetfsX44 fs
262 88 c.262T>C/ p.Trp88Arg missense
264 88 c.264G>T/ p.Trp88Cys missense
266 89 c.266T>A/ p.Leu89His missense
266 89 c.266T>C/ p.Leu89Pro missense
266 89 c.266T>G/ p.Leu89Arg missense
267 89 c.267_271del/ p. Asn90ArgfsX40 fs
272 91 c.272insCAACT / p.Phe91SerfsX3  fs
273 91 c.273G>A / p.Phe91Leu missense
272 91 c.272_280del9/ p.Phe91X in frame
273 91 c.273insT/ p.Asp92ArgfsX40 fs
275 92 c.275_285del11/ p.Asp92AlafsX36 fs
276 92 c.276_279delCGGC/ p.Asp92GlufsX66 fs
278 93 c.278G>A / p.Gly93Asp missense
278 93 c.279C>G / p.Gly93Glu missense
280 94 c.280G>T/ p.Glu94X nonsense
288 96 c.288delG/ p.Gln96HisfsX63 fs
292 98 c.292T>A/ p.Tyr98Asn missense
294 98 c.294delC/ p.Pro99GlnfsX60 fs
294 98 c.294C>G/p.Tyr98X nonsense
296 99 c.296delC / p.Pro99GlnfsX60 fs
299 100 c.299delC/ p.Thr100SerfsX59 fs
302 101 c.302T>C/p.Leu101Pro missense
316 106 c.316_317delGG/ p.Gly106ProfsX25 fs
319 107 c.319_340del22/ p.Arg107ValfsX45 fs
323 108 c.323insC/ p.Arg108ProfsX24 fs
330 110 c.330insTCCA/ p. Ser111ProfsX22 fs
333 111 c.333C>A/ p.Ser111Arg missense
334 112 c.334T>G/p.Tyr112Asp missense
340 114 c.340G>C/ p.Gly114Arg missense
340+1 c.IVS1+1G>T (c.340+1G>T) splice mut
340+1 c.IVS1+1G>A (c.340+1G>A) splice mut
340+2 c.IVS+2T>G (c.340+2T>G) splice mut
94 
 
Supplementary table 1: List of all VHL mutations (exon 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exon 2 341 114 c.341G>A/ p.Gly114Asp missense
341-1 114 IVS1-1_342delGGT (c.[341-1]_342delGGT) splice mut
341-1 114 c.IVS1-1G>A (c.341-1G>A) splice mut
342 115 c.342insG/ p.His115SerfsX17 fs
343 115 c.343C>A/p.His115Asn missense
343 115 c.343C>T/ p.His115Tyr missense
343 115 c.343_344delCA/ p.His115ProfsX16 fs
344 115 c.344A>T/p.His115Leu missense
349 117 c.349T>C/ p.Trp117Arg missense
350 117 c.350G>T/p.Trp117Leu missense
350 117 c.350G>C/p.Trp117Ser missense
350 117 c.350insT/ p.Trp117LeufsX15 fs
351 117 c.351G>T/ p.Trp117Cys missense
353 118 c.353T>C/ p.Leu118Pro missense
357 119 c.357C>A/p.Phe119Leu missense
361 121 c.361_363delGAT/ p.Asp121del in frame
361 121 c.361G>T/p.Asp121Tyr missense
362 121 c.362A>G/ p.Asp121Gly missense
367 123 c.367delG/ p.Thr124HisfsX35 fs
370 124 c.370A>G/ p.Thr124Ala missense
370 124 c.370delA/ p. Thr124HisfsX35 fs
371 124 c.371_378del/ p.Thr124ArgfsX5 fs
374 125 c.374_380del/ p.His125ArgfsX32 fs
375 125 c.375insA/ p.His125fsX7 fs
383 128 c.383T>A/p.Leu128His missense
388 130 c.388G>T/p.Val130Phe missense
389 130 c.389T>A/p.Val130Asp missense
393 131 c.393insA/ p.Asn131LysfsX4 fs
394 132  c.394delC/ p.Gln132LysfsX27 fs
395 132 c.395A>C/p.Gln132Pro missense
397 133 c.397delA/ p.Thr133LeufsX26 fs
398 133 c.398delC/ p.Thr133MetfsX26 fs
400 134 c.400_403delGAAT/ p.Glu134TyrfsX24 fs
402 134 c.402delA/ p.Glu134AspfsX25 fs
403 135 c.403insA/ p.Leu135IlefsX9 fs
404 135 c.404delT/ p.Leu135TyrfsX24 fs
404 135 c.404T>A/ p.Leu135X nonsense
405 135 c.405_406insTT/ p.Leu135fsPheX25 fs
405 135 c.405insT/ p.Leu135PhefsX9 fs
406 136 c.406insATTA/ p.Phe136IlefsX9 fs
407 136 c.407ins9/ p.Phe136TyrfsX82 in frame
407 136 c.407insATAT/ p.Phe136TyrfsX9 fs
409 137 c.409delG/ p.Val137CysfsX22 fs
420 140 c.420ins44/ p.Asn141ArgfsX4 fs
421 141 c.421delA/ p.Asn141MetfsX18 fs
424 142 c.424_439del/ p.Val142PhefsX12  fs
426 143 c.426delT/ p. Asp143ThrfsX16 fs
426 143 c.426delT/ p.Asp143ThrfsX16; 432: sequence repeat from 377 fs
433 145 c.433C>T/ p.Gln145X nonsense
444 148 c.444delT/ p.Phe148 LeufsX11 fs
444 148 c.444delT/ p.Phe148 LeufsX11 fs
445 149 c.445insT/ p.Ala149CysfsX25 fs
452 151 c.452T>G/ p.Ile151Ser missense
452 151 c.452T>C/ p.Ile151Thr missense
456 152 c.456insC/ p. Leu153ThrfsX21 fs
458 153 c.458T>C/ p.Leu153Pro missense
462 155 c.462delA/ p.Val155CysfsX4 fs
341-1  c.IVS1-1G>A (c.341-1G>A) splice mut
341-2 c.IVS1-2A>T (c.341-2A>T) splice mut
341-2 c.IVS1-2 A>G (c.341-2 A>G) splice mut
341-2 IVS1-2 A>G (c.341-2 A>G) splice mut
463+1 c.IVS2+1G>A (c.463+1G>A) splice mut
463+1 IVS2+1delG (c.463+1delG) splice mut
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Supplementary table 1: List of all VHL mutations (exon 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exon 3 468 157 c.468_470delTAC/ p.Thr157_ Thr157del in frame
472 158 c.472C>G/ p.Leu158Val missense
472 158 c.472C>G/ p.Leu158Val missense
477 159 c.477A>T/p.Lys159Asn missense
481 161 c.481C>T/ p.Arg161X nonsense
481 161 c.481C>T/ p.Arg161X nonsense
481 161 c.481C>T/ p.Arg161X nonsense
481 161 c.481insAG/ p.Arg161SerfsX10 fs
482 161 c.482G>C/p.Arg161Pro missense
482 161 c.482G>A/p.Arg161Gln missense
491 164 c.491_494delAGGT/ p.Gln164LeufsX5 fs
499 167 c.499_510del12/ p.Arg167_Val170del in frame
501 167 c.501delG/ p.Ser168AlafsX2 fs
506 169 c.506T>C/ p.Leu169Pro missense
506 169 c.506T>C/ p.Leu169Pro missense
507 169 c.507_508delAG/ p. Val170 GlnfsX3 fs
509 170 c.509T>A/ p.Val170Asp missense
517 173 c.517G>T/p.Glu173X nonsense
520 174 c.520delA/ p.Asn174IlefsX28 fs
522 174 c.522_523delTT/ p.Asn174LysfsX81    fs
523 175 c.523delT/ p.Tyr175ThrfsX27 fs
531 177 c.531delA/ p.Arg177fsX25 fs
531 177 c.531delA/ p.Arg177SerfsX25  fs
538 180 c.538A>G/ p.Ile180Val missense
540 180 c.540_564del25/ p.Val181LysfsX14 fs
551 184 c.551T>C/ p.Leu184Pro missense
551 184 c.551T>C/ p.Leu184Pro missense
551 184 c.551T>C/ p.Leu184Pro missense
551 184 c.551T>C / p.Leu184Pro missense
551 184 c.552C>T/ p.Leu184Pro missense
557 186 c.557_561delAAGAT/ p.Glu186AlafsX68  fs
565 189 c.565G>T/p.Glu189X nonsense
586 196 c.586A>T/p.Lys196X nonsense
612 205 c.612insA/ p.Arg205AlafsX51 fs
619 207 c.619insT/ p.Ala207CysfsX49 fs
642 214 c.642 A>C/ p.X214Cys missense
464-1 c.IVS2-1G>A (c.464-1G>A) splice mut
464-2 c.IVS2-2A>T (c.464-2A>T) splice mut
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Supplementary table 1: List of all VHL mutations (additional 104 cases all exons) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional 104 cases
nt AA codon Mutation Mutation consequence
Exon 1 161 54 c.161_162delTG/p.Met54ArgfsX77 fs
163 55 c. 163insA/p.Glu55ArgfsX77 splice mut
163 55 c.163delG/p.Glu55ArgfsX11 fs
167 56 c.167_168delCC/p.Ala56GlyfsX75 fs
172 58 c172delC/p.Arg58GlyfsX9 fs
193 65 c.193T>A/p.Ser65Thr missense
194 65 c.194C>T/p.Ser65Leu missense
194 65 c. 194C>A/p.Ser65X nonsense
194 65 c.194C>T/p.Ser65Leu missense
194 65 c.194C>T/p.Ser65Leu missense
203 68 c.203C>A/p.Ser68X nonsense
226 76 c.226_236del10/p.Phe76AlafsX79 fs
227 76 c.227_229del3/p.Phe76del in frame
233 78 c. 233A>G/p.Asn78Ser missense
238 80 c.238A>C/p.Ser80Arg missense
238 80 c.238A>C/p.Ser80Arg missense
240 80 c.240T>A/p.Ser80Arg missense
254 85 c. 254_262del9/p.Leu85_Trp88delinsArg in frame
254 85 c. 254_262del9/p.Leu85_Trp88delinsArg in frame
262 88 c. 262T>G/p.Trp88Gly missense
262 88 c. 262T>A/p.Trp88Arg missense
268 90 c.268_273del/p.Asn90_Phe91del in frame
314 105 c. 314insA/p.Thr105AsnfsX27 fs
315 106 c.315_318del4/p.Gly106AlafsX51 fs
327 110 c.327insA/p.His110ProfsX22 fs
335 112 c.335_340+1del7/p.Tyr112PhefsX45 splice mut
340 114 c.340G>T/p.Gly114Cys missense
340+1 c.IVS1+1G>A (c.340+1G>A) splice mut
340+2 c.IVS1+2T>A (c.340+2T>A) splice mut
340+1 c.IVS1+1G>A (c.340+1G>A) splice mut
Exon 2 345 116 c.345_364del/p.Leu116ArgfsX9 fs
345 116 c.345insC/p.Leu116ProfsX15 fs
345 115 c.345C>G/p.His115Gln missense
349 117 c.349delT/p.Trp117GlyfsX42 fs
349 117 c.349T>C/p.Trp117Arg missense
350 117 c. 350delG/p.Trp117CysfsX42 fs
351 117 c. 351G>A/p.Trp117X nonsense
376 126 c.376insG/p.Asp126GlyfsX5 fs
383 128 c.383T>C/p.Leu128Pro missense
385 135 c.385_404dup/Leu135PhefsX31 fs
397 133 c.397delA/p.Thr133LeuFsX26 fs
405 135 c. 405-406delAT/p.Leu135PhefsX7 fs
407 136 c.407T>C/p.Phe136Ser missense
423 141 c.423insA/p.Asn141LysfsX2 fs
430 144 c.430G>T/p.Gly144X nonsense
435 145 c.435delG/p.Gln145HisfsX13 fs
437 146 c.437C>T/p.Pro146Leu missense
444 148 c.444delT/p.Phe148LeufsX10 fs
458 153 c.458T>C/p.Leu153Pro missense
458 153 c. 458T>C/p.Leu153Pro missense
Exon 3 fs exon 3 frameshift fs
473 158 c.493T>A/p.Leu158Gln missense
481 161 c.481C>T/p.Arg161X nonsense
484 162 c.484T>C/p.Cys162Arg missense
484 162 c.484T>C/p.Cys162Arg missense
493 165 c.493_503del/p.Val165ProfsX5 fs
497 167 c.497_505del9/p.Arg167ValdelSerLeu in frame
509 170 c.509_512del4/p.Val170GlyfsX31 fs
515 172 c.515delC/p.Pro172LeufsX29 fs
524 175 c. 524insA/p.Tyr175X nonsense
533 178 c. 533T>C/p.Leu178Pro missense
546 183 c.546insG/p.Ser183ValfsX32 fs
548 183 c.548C>T/p.Ser183Leu* missense
555 185 c.555C>A/p.Tyr185X nonsense
580 194 C.580_583delinsAA/p.Val194LysfsX61 fs
586 196 c.586A>T/p.Lys196X nonsense
598 200 c.598C>T/p.Arg200Trp* missense
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Supplementary S1: Information on pVHL’s binding partners 
Preferentially altered binding domains 
HIF1αN (alias FIH1) is an inhibitor of the α subunit of HIF1 that interacts with pVHL and HIF1α 
to mediate repression of HIF1 transcriptional activity [145] by preventing HIF-1α from binding 
to p300/CBP [146]. 
BCL2L11 is an apoptosis facilitator leading to the expression of BIM(EL) protein which can be 
stabilized by VHL wild-type protein [147].  
HIF1α is the alpha subunit of transcription factor hypoxia-inducible factor-1, which is formed by 
the association of an alpha and a beta subunit. HIF-1 is a regulator of cellular response to hypoxia 
that activates transcription of many genes for metabolism, angiogenesis and apoptosis for 
adaptation to hypoxia. One of pVHL major role is to facilitate the oxygen-dependent 
ubiquitination of HIF1 for proteasomal degradation, leading to downregulation of HIF target 
genes [148]. 
HIF2α is the alpha subunit of hypoxia-inducible factor-2, a transcription factor responding to 
hypoxia and involved in the induction of genes regulated by oxygen. As HIF1α, its ubiquitination 
is mediated by pVHL which acts as a downregulator of HIF2α [149]. 
RPB1 is the largest subunit of the RNA polymerase II complex that can be ubiquitinated by  
pVHL thus regulating its expression in RCC cells [150]. Levels of Rpb1 are significantly higher 
in RCC tumors compared with normal kidneys and RCC tumors with pVHL wild-type show 
higher levels of Rpb1 than tumors with VHL mutations [46]. 
PRKCZ is a serine/threonine kinase which is recruited by pVHL causing ubiquitination and 
degradation thus influencing cell polarity [151, 152].  
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aPKC-λ/ι is a tyrosine kinase member of the protein kinase C family and aPKC isotypes are 
involved in the regulation of cell growth and apoptosis and interact directly with the β-domain of 
pVHL [153]. 
EEF1α1 encodes the alpha subunit of the elongation factor-1 complex, which is responsible for 
the enzymatic delivery of aminoacyl tRNAs to the ribosome. This translation factor interacts 
specifically with the transcription-dependent nuclear export motif of VHL, mediating the nuclear 
export of pVHL [48]. 
CCT-ζ-2 is a molecular chaperone protein, member of the chaperonin containing TCP1 complex 
(CCT). CCT-ζ-2 mediates the proper folding and assembly of the VCB complex and some VHL 
mutations have been demonstrated to impair this interaction [49, 115]. 
Cullin2 is a negative regulator of cell cycle and associates with pVHL in the VBC complex [154, 
155]. 
Spared binding domains 
Nur77 is a nuclear transcription factor that promotes cancer cell growth when located in the 
nucleus or induces apoptosis when translocated to mitochondria. Nur77 indirectly stabilizes HIF-
α by binding to pVHL, thus increasing HIF1α transcriptional activity [156]. 
VBP1 interacts with pVHL to form an intracellular complex. VBP1 is a chaperone protein, and 
pVHL plays a role in its transport from the perinuclear granules to the nucleus or cytoplasm but 
VBP1 implication in ccRCC remains unknown [116]. 
Other interactors 
NEDD8 is an ubiquitin-like protein playing an important role in cell cycle control. NEDD8 
association with pVHL prevents the formation of the VCB complex [157]. 
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VDU1 is able to be ubiquitinated via a pVHL-dependent pathway for proteasomal degradation, 
and VHL mutations that disrupt the interaction between VDU1 and pVHL abrogate the 
ubiquitination of VDU1 [47, 158]. 
VDU2 can also be ubiquitinated and degraded in a pVHL-dependent manner, preventing it from 
rescuing HIF1α degradation by deubiquitination [158]. 
PRKCD is a serine/threonine kinase involved in diverse cellular signaling pathways such as 
growth, apoptosis, and differentiation. pVHL blocks the interaction of PRKCD with IGF1R to 
decrease tumor progression [159]. 
p53 is a tumor suppressor protein responding to diverse cellular stresses such as DNA damage 
and hypoxia to regulate expression of target genes leading to cell cycle arrest, apoptosis, 
senescence, DNA repair, or changes in metabolism. Recently p53 has been shown to interact with 
pVHL. This interaction prevents p53 ubiquitination by the Mdm2 protein, therefore leading to 
p53 stabilization and transactivation of p53 target genes for apoptosis and cell cycle arrest [64, 
65, 67, 78]. 
VHLAK, also known as zinc finger protein 197, is a regulatory and transcription factor involved 
in transcriptional regulation that acts as a negative regulator of HIF-1αlpha transactivation. VHL 
protein recruits VHLAK to repress HIF-1αlpha transcriptional activity and HIF-1αlpha-induced 
VEGF expression [160]. 
RPB7 is the seventh largest subunit of the RNA polymerase II complex. VHL protein facilitates 
its ubiquitination and proteasomal degradation and decreases its nuclear accumulation. pVHL can 
also suppress hsRPB7-induced VEGF promoter transactivation, mRNA expression and VEGF 
protein secretion [161]. 
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SP1 is implicated in regulation of genes that control multiple cellular processes, including cell 
cycle, apoptosis, and DNA damage. pVHL inhibits sp1 interaction with PKC zeta and Sp1-
dependent transcriptional regulation of VEGF expression and thus tumor angiogenesis [162]. 
HuR is a RNA binding protein regulating gene expression that is highly expressed in many 
cancers including ccRCC where it is activated in the early tumor stages. HuR induces VEGF and 
IGF1R mRNA stabilization and pVHL interaction with HuR has been demonstrated to 
antagonize these effects [163-165]. 
TUBA4A is a member of the tubulin superfamily and one of the major components of 
microtubules. pVHL binds α-tubulin and stabilizes it, stabilizing microtubules [166-168].  
KIF3A is a member of the kinesin protein family mediating pVHL’s interaction with 
microtubules [167]. 
JADE1 is involved in apoptosis and differentiation in epithelia and ubiquitinates βcatenin for 
degradation. This protein is stabilized by interaction with pVHL and this stabilization is VHL 
mutation-dependent [45, 169, 170]. 
CARD9 is an activator of BCL10 leading to NFKB activation and also acts as a positive regulator 
of apoptosis. VHL protein associates with CARD9 and promotes its phosphorylation by CK2, 
thus inhibiting its activation of NFkB [171]. 
EloC is a subunit of the transcription factor B composed of elongins A/A2, B and C and 
activating elongation by RNA polymerase II. EloC is also one component of the VCB complex 
for negative regulation of HIFs [172]. 
TBP1 is a regulator of proteasome, ATPase subunit contributing to the E3 ubiquitin ligase 
function of the VHL protein. TBP-1 has been show to interact with the β-domain of pVHL and to 
form a complex with pVHL and HIF1α to promote HIF1α degradation [173]. 
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CK1 is a serine/threonine kinase involved in the regulation of the G1-checkpoint. CK1 
phosphorylates pVHL at Ser72 which is a priming event to phosphorylation of pVHL’s Ser68 by 
GSK3 [174]. 
GSK3 is a glycogen synthase kinase that phosphorylates pVHL at position Ser68 thus negatively 
regulating microtubule stabilization by pVHL [174]. 
CK2 is a protein involved in regulation of cell growth that phosphorylates the acidic domain of 
pVHL to stabilize its interaction with fibronectin [175].  
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Supplementary table 2: List of missense mutations, stability and disease association prediction 
 
 
 
  
Stability and disease prediction ddG nt AA codon Mutation Interacting partners
highly destabilizing -5.07 221 74 c.221T>A/p.Val74Asp HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
cause protein malfunction and disease -3.53 245 82 c.245G>C/ p.Arg82Pro HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-3.8 251 84 c.251T>A/p.Val84Glu HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-2.86 262 88 c. 262T>G/p.Trp88Gly HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ
-2.46 262 88 c.262T>C/ p.Trp88Arg HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ
-2.46 262 88 c. 262T>A/p.Trp88Arg HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ
-4.04 266 89 c.266T>C/ p.Leu89Pro HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ
-3.19 266 89 c.266T>A/ p.Leu89His HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ
-3.12 266 89 c.266T>G/ p.Leu89Arg HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ
-3.36 278 93 c.279C>G / p.Gly93Glu HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9
-6.48 302 101 c.302T>C/p.Leu101Pro HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1
-2.99 334 112 c.334T>G/p.Tyr112Asp HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1
-2.53 341 114 c.341G>A/ p.Gly114Asp HIF1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1
-3.1 343 115 c.343C>A/p.His115Asn HIF1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1
-2.15 345 115 c.345C>G/p.His115Gln F1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1/CCT-ζ
-2.14 349 117 c.349T>C/ p.Trp117Arg F1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1/CCT-ζ
-2.14 349 117 c.349T>C/p.Trp117Arg F1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1/CCT-ζ
-2.52 350 117 c.350G>C/p.Trp117Ser F1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1/CCT-ζ
-4.04 353 118 c.353T>C/ p.Leu118Pro HIF1αN/VHLAK/BCL2L11/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1/CCT-ζ-2
-6.48 383 128 c.383T>C/p.Leu128Pro HIF1αN/VHLAK/BCL2L11/EEF1A1
-2.43 383 128 c.383T>A/p.Leu128His HIF1αN/VHLAK/BCL2L11/EEF1A1
-5.07 389 130 c.389T>A/p.Val130Asp HIF1αN/VHLAK/BCL2L11/PRKCD/EEF1A1
-8.69 395 132 c.395A>C/p.Gln132Pro HIF1αN/VHLAK/BCL2L11/PRKCD/EEF1A1
-4.9 407 136 c.407T>C/p.Phe136Ser HIF1αN/VHLAK/BCL2L11/PRKCD/EEF1A1/TBP1
-4.99 452 151 c.452T>G/ p.Ile151Ser HIF1αN/VHLAK/PRKCD/CCT-ζ-2/TBP1
-4.34 452 151 c.452T>C/ p.Ile151Thr HIF1αN/VHLAK/PRKCD/CCT-ζ-2/TBP1
-2.28 482 161 c.482G>C/p.Arg161Pro NEDD8/VHLAK/p53/Nur77/EloC/HuR
-2.05 509 170 c.509T>A/ p.Val170Asp VHLAK/Nur77/EloC/HuR/EloB
-3.7 551 184 c.551T>C/ p.Leu184Pro VHLAK/Nur77/HuR/Cullin2
-3.7 551 184 c.551T>C/ p.Leu184Pro VHLAK/Nur77/HuR/Cullin2
-3.7 551 184 c.551T>C/ p.Leu184Pro VHLAK/Nur77/HuR/Cullin2
-3.7 551 184 c.551T>C / p.Leu184Pro VHLAK/Nur77/HuR/Cullin2
-3.7 551 184 c.552C>T/ p.Leu184Pro VHLAK/Nur77/HuR/Cullin2
destabilizing -1.41 214 72 c.214T>C/p.Ser72Pro CK1/HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
non-disease-associated -1.31 234 78 c.234T>A/p.Asn78Lys HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-1.31 234 78 c.234T>A/p.Asn78Lys HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-1.31 234 78 c.234T>G/p.Asn78Lys HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-1.92 238 80 c.238A>C/p.Ser80Arg HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-1.92 238 80 c.238A>C/p.Ser80Arg HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-1.92 240 80 c.240T>A/ p.Ser80Arg HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-1.92 240 80 c.240T>A/ p.Ser80Arg HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-1.92 240 80 c.240T>A/p.Ser80Arg HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-1.95 278 93 c.278G>A / p.Gly93Asp HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9
-1.35 292 98 c.292T>A/ p.Tyr98Asn HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1
-1.86 350 117 c.350G>T/p.Trp117Leu F1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1/CCT-ζ
-1.05 388 130 c.388G>T/p.Val130Phe HIF1αN/VHLAK/BCL2L11/PRKCD/EEF1A1
-1.6 477 159 c.477A>T/p.Lys159Asn NEDD8/VHLAK/p53/Nur77/EloC/HuR
-1.87 506 169 c.506T>C/ p.Leu169Pro VHLAK/Nur77/EloC/HuR
-1.87 506 169 c.506T>C/ p.Leu169Pro VHLAK/Nur77/EloC/HuR
slightly destabilizing -0.94 193 65 c.193T>A/p.Ser65Thr HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/RPB1
non-disease-associated -0.94 193 65 c.193T>A/p.Ser65Thr HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/RPB1
-0.86 239 80 c.239G>A/ p.Ser80Asn HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-0.52 333 111 c.333C>A/ p.Ser111Arg HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1
-0.55 357 119 c.357C>A/p.Phe119Leu HIF1αN/VHLAK/BCL2L11/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1/CCT-ζ-2
-0.8 458 153 c.458T>C/ p.Leu153Pro HIF1αN/VHLAK/PRKCD/CCT-ζ-2/TBP1
-0.8 458 153 c.458T>C/p.Leu153Pro HIF1αN/VHLAK/PRKCD/CCT-ζ-2/TBP1
-0.8 458 153 c. 458T>C/p.Leu153Pro HIF1αN/VHLAK/PRKCD/CCT-ζ-2/TBP1
-0.63 472 158 c.472C>G/ p.Leu158Val VHLAK/p53/Nur77/EloC/HuR
-0.63 472 158 c.472C>G/ p.Leu158Val VHLAK/p53/Nur77/EloC/HuR
-0.8 533 178 c. 533T>C/p.Leu178Pro VHLAK/Nur77/HuR
neutral -0.41 202 68 c.202T>A/p.Ser68Thr GSK3/HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
non-disease-associated -0.21 233 78 c.233A>G/ p.Asn78Ser HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
-0.21 233 78 c. 233A>G/p.Asn78Ser HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
0.05 340 114 c.340G>T/p.Gly114Cys HIF1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1
0.44 362 121 c.362A>G/ p.Asp121Gly HIF1αN/VHLAK/BCL2L11/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1
-0.14 370 124 c.370A>G/ p.Thr124Ala HIF1αN/VHLAK/BCL2L11/EEF1A1
0.11 473 158 c.493T>A/p.Leu158Gln VHLAK/p53/Nur77/EloC/HuR
-0.19 482 161 c.482G>A/p.Arg161Gln NEDD8/VHLAK/p53/Nur77/EloC/HuR
0.37 484 162 c.484T>C/p.Cys162Arg VHLAK/p53/Nur77/EloC/HuR
0.37 484 162 c.484T>C/p.Cys162Arg VHLAK/p53/Nur77/EloC/HuR
-0.01 538 180 c.538A>G/ p.Ile180Val VHLAK/Nur77/HuR
slightly stabilizing 0.68 232 78 c.232A>T/ p.Asn78Tyr HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
non-disease-associated 0.79 256 86 c.256C>A/ p.Pro86Thr HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
0.7 273 91 c.273G>A / p.Phe91Leu HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ
0.81 437 146 c.437C>T/p.Pro146Leu HIF1αN/VHLAK/PRKCD/TBP1
stabilizing 1.57 194 65 c.194C>T/ p.Ser65Leu HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/RPB1
non-disease-associated 1.57 194 65 c.194C>T/p.Ser65Leu HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/RPB1
1.57 194 65 c.194C>T/p.Ser65Leu HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/RPB1
1.57 194 65 c.194C>T/p.Ser65Leu HIF1αN/VDU1/USP33/VDU2/USP20/RPB7/VHLAK/BCL2L11/RPB1
1.36 257 86 c.257C>A/ p.Pro86His HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1
1.22 340 114 c.340G>C/ p.Gly114Arg HIF1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1
1.36 343 115 c.343C>T/ p.His115Tyr HIF1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1
1.2 351 117 c.351G>T/ p.Trp117Cys F1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1/CCT-ζ
1.49 361 121 c.361G>T/p.Asp121Tyr HIF1αN/VHLAK/BCL2L11/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1
1.02 548 183 c.548C>T/p.Ser183Leu VHLAK/Nur77/HuR/Cullin2
1.64 598 200 c.598C>T/p.Arg200Trp VHLAK/Nur77/VBP1
highly stabilizing 3.41 264 88 c.264G>T/ p.Trp88Cys HIF1αN/RPB7/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ
cause protein malfunction and disease 2.24 344 115 c.344A>T/p.His115Leu HIF1αN/VHLAK/BCL2L11/HIF1α/EPAS1/RPB1/PRKCZ/CARD9/TUBA4A/KIF3A/SP1/JADE1/PRKCD/aPKC-λ/ι/EEF1A1
In italic: two mutations in the same tumor
Destabilizing
Neutral
Stabilizing
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